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ABSTRACT OF THE DISSERTATION
Identification and Characterization of a Selective Inhibitor of the PIM-1 Kinase
by
Sheldon Levon Holder
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, September 2005
Dr. Michael Lilly, Chairperson

The PIM-1 kinase is a serine/threonine kinase that has been implicated in the
development of many human cancers, including leukemias, lymphomas, and prostate
cancer. We have endeavored to identify and characterize a selective inhibitor of the PIM1 kinase. Such an inhibitor would have utility as a laboratory tool for the study of PIM-1
kinase function and as a template for the design of molecular therapeutics for diseases in
which PIM-1 kinase activity is dysregulated.
Using phage display techniques we identified the peptide, HGVKKRPHNPYG, as
a probable pseudosubstrate of the PIM-1 kinase with inhibitory activity in the low
micromolar range in in vitro kinase assays. However, the peptide lacked sufficient
potency for our objectives; hence we employed a second approach - the computational
design of a novel PIM-1 kinase antagonist.
We created a homology model of the PIM-1 kinase that was subsequently
determined to be structurally similar to a recently published crystal structure of the PIM-1
kinase. Docking studies using the PIM-1 kinase model demonstrated that the AFFINITY
module of Insightll, under the parameters employed, was unable to accurately predict the
potency of known PIM-1 kinase inhibitors. Consequently, we utilized comparative
molecular field analysis, which resulted in a strong correlation of predicted IC50 vs.

xiv

experimental IC50 values for known flavonoid inhibitors of the PIM-1 kinase. Thus we
have created the first predictive model that may be used for the rational design of small
molecule inhibitors of the PIM-1 kinase.
We have also performed an extensive screen of small molecules with structures
similar to known kinase inhibitors and identified quercetagetin as a potent inhibitor of the
PIM-1 kinase, with an in vitro IC50 of 0.34 pM. Lineweaver-burk analyses of the
reaction kinetics demonstrated that quercetagetin is an ATP competitive inhibitor the
PIM-1 kinase. We have also determined that quercetagetin is selective for the PIM-1
kinase over many other kinases and that quercetagetin successfully inhibits PIM-1 kinase
activity in mammalian cells. Therefore quercetagetin may be an effective tool for the
laboratory study of the PIM-1 kinase, and may serve as a template for the design of
molecular therapeutics directed against the PIM-1 kinase.
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CHAPTER ONE
INTRODUCTION
Protein Phosphorylation
Protein phosphorylation is the process by which a phosphate group is transferred
from adenosine triphosphate (ATP) to a substrate protein. A family of enzymes called
kinases typically catalyzes the biochemical reaction. The reverse reaction of
dephosphorylation is catalyzed by a group of enzymes called phosphatases. The net
activity of kinases and phosphatases ultimately determines the phosphorylated state of a
protein.
Much of the early work elucidating reversible phosphorylation as a biological
regulatory mechanism was conducted by Edmond H. Fischer and Edwin G. Krebs. Their
work involved the enzyme phosphorylase isolated from rabbit skeletal muscle, which
exists in an active (phosphorylase a) and inactive (phosphorylase b) form. Krebs and
Fischer demonstrated that inactive phosphorylase b is converted to active phosphorylase
ci by a phosphorylation reaction catalyzed by phosphorylase kinase(l-3). The reverse
reaction from active phosphorylase a to inactive phosphorylase b was shown to be
catalyzed by phosphorylase phosphatase(4-7). Hence it was shown that the enzymatic
activity of phosphorylase is regulated by phosphorylation (see Figure 1). The
identification of this regulatory mechanism established protein phosphorylation as a
biologically important regulatory mechanism and earned Krebs and Fischer the 1992
Nobel Prize in Physiology or Medicine.

1

phosphorylase kinase
>

<

phosphorylase phosphatase
Phosphorylase b

Phosphorylase a

(inactive)

(active)

Figure 1. The activity of phosphorylase is regulated by phosphorylation.
Phosphorylase is activated by a phosphorylation reaction catalyzed by phosphorylase
kinase. The reverse reaction, catalyzed by phosphorylase phosphatase, inactivates the
enzyme. The large red oval represents phosphorylase and the small yellow circle
represents a phosphate group.

The effect of phosphorylation on the activity of an enzyme substrate varies
depending on the enzyme. As in the case of phosphorylase alb, some enzymes are
activated by phosphorylation. Other enzymes, such as cylclin dependent kinase 2, are
inactivated by phosphorylation. By influencing the activity of enzymes, phosphorylation
is an important method of managing cellular functions.
The effects of phosphorylation are not limited to manipulating enzyme activity.
Kinases also phosphorylate non-enzymatic proteins, thereby influencing the proteins’
binding partners. The regulation of protein-protein associations is a second mechanism
by which kinases regulate cellular functions.

1.2. Kinases as Molecular Targets for Therapeutic Intervention in Human
Malignancies
As stated previously, protein kinases are enzymes that catalyze the transfer of a
phosphate group from ATP to a substrate protein. Perhaps the most extensively
characterized kinases are the tyrosine and serine/threonine kinases found in eukaryotic
organisms. Tyrosine kinases phosphorylate proteins in the side chains of tyrosine
residues. Similarly, serine/threonine kinases phosphorylate proteins on the side chains of
2

serine and threonine residues. Histidine kinases, which have been described in
prokaryotic organisms, phosphorylate proteins on the side chains of histidine residues.
Numerous cellular processes such as proliferation, differentiation, and apoptosis,
are regulated by kinases within tightly controlled signal transduction pathways.
Dysregulation of these kinases has been implicated in the development of many human
diseases. For example, the development of chronic myelogenous leukemia (CML) has
been attributed to a chromosomal translocation resulting in the continuously active fusion
protein - BCR-ABL kinase(8-l 1). Similarly, genetic mutations in the Flt-3 and c-Kit
kinases have been implicated in the development of acute myelogenous leukemia (AML)
and gastrointestinal stromal tumors (GIST), respectively(12-14). As a result there has
been growing interest in specific kinase inhibitors as potential anti-cancer therapeutics
(for review see (15)), with several small molecule specific kinase inhibitors already
undergoing clinical trials (for review see (16)).
Perhaps the most dramatic case-in-point is that of imatinib mesylate (formerly
called STI571 and now marketed under the tradename Gleveec®) for the treatment of
CML. As previously stated, CML is caused by the action of a constitutively active
tyrosine kinase called BCR-ABL(8-11). The fusion kinase is the result of a reciprocal
translocation between chromosome 9 and chromosome 22 that brings together the genes
bcr and abl{\l) (also known as the Philadelphia chromosome; Ph). The BCR-ABL
tyrosine kinase continuously activates signal transduction pathways and serves as the
driving force for the cellular proliferation commonly observed in CML.
Imatinib mesylate is an inhibitor of the BCR-ABL tyrosine kinase. It functions by
competitively binding at the ATP-binding site of the BCR-ABL kinase. The result is an
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inability of the kinase to phosphorylate its cellular substrates and hence a significant
reduction in BCR-ABL mediated signal transduction( 18). In pre-clinical studies
Gleveec® was able to induce apoptosis or arrest the growth of hematological cells
expressing BCR-ABL, while having no effect on normal cells( 19-21). Subsequent
clinical trials, in which Gleevec® was given orally to patients with chronic phase CML
for whom interferon alpha treatment had already failed, yielded promising results. Fiftythree out of 54 patients who were given daily doses of 300 mg or more achieved
complete hematological responses, i.e. a white cell count of less than 10,000 per cubic
mm and a platelet count of less than 450,000 per cubic mm. Additionally, up to 13% of
this same population of patients achieved complete cytogenetic remission, i.e. after
analysis of 20 cells in metaphase, none of the cells were positive for the 9:22
chromosome translocation. Moreover, Gleevec® was well tolerated by patients.
Myalgia, thrombocytopenia, and neutropenia were the most serious of adverse effects.
and nausea, myalgia, edema, and diarrhea were the most common side-effects(18). The
benefits of Gleevec® being quite clear, it was not long before it became available as an
FDA approved drug for the treatment of CML. Today Gleevec® is indicated for newly
diagnosed Ph+ CML in adults, and is meeting with continued success.
In addition to tyrosine kinases, serine/threonine kinases are also being targeted for
the treatment of human malignancies. One such target is a family of serine/threonine
kinases called cyclin-dependent kinases (CDKs) that are major regulators of the
eukaryotic cell cycle(22-24). CDK2 and CDK4/6 are involved in controlling the
progression of cells from the first gap phase of the cell cycle (Gl) into the DNA synthesis
phase (S)(25). Similarly, CDK1 (also called cdc2) acts to encourage the progression of
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cells from the second gap phase (G2) of the cell cycle into mitosis (M)(26).
in CDKs, endogenous CDK inhibitors (such as p!6

INK4a

Alterations

21wan/ciPi;and p27M)and

cyclins (protein binding partners of CDKs that positively regulate CDK function) have
been demonstrated in human malignancies(27;28). Because CDKs are fundamental
regulators of the cell cycle, and alterations in their function have been implicated in the
development of human malignancies, CDKs have become attractive targets for the
development of therapeutic selective kinase inhibitors.
Inhibiting CDK activity has been shown to cause apoptosis in tumor cells, but not
in normal cells(29;30). While many CDK inhibitors are currently being developed, there
are at least two cyclin-dependent kinase inhibitors that have shown sufficient efficacy in
laboratory experiments to undergo clinical trials - Cyc202 and flavopiridol.
Cyc202, also called seliciclib, is a cyclin-dependent kinase inhibitor that has been
shown to posses potent antitumor activity(31). Phase I clinical studies have demonstrated
that seliciclib can be administered to patients at concentrations sufficiently high enough
to affect tumor cells, without causing severe adverse effects in patients. Phase II clinical
trials are currently being conducted using seliciclib in combination with other cytotoxic
drugs for the treatment of non-small cell lung cancer, and as a monotherapy for the
treatment of B-cell malignancies. Currently, the results of the phase II trials are not yet
available.
Flavopiridol has also been identified as a CDK inhibitor(32;33). Laboratory
studies demonstrate that flavopiridol inhibits the activity of cdkl, cdk2, cdk4, cdk6, and
cdk7. In a recent clinical study conducted in 26 patients with fludarabine-refractory
chronic lymphocytic leukemia, treatment with flavopiridol did not result in any complete
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responses (where no evidence of cancer cells could be detected); neither were any partial
responses observed (where a reduction in the total amount of cancer was detected)(34).
Phase II studies in patients with metastatic malignant melanoma(35), metastatic
androgen-independent prostate cancer(36), advanced colorectal cancer(37), mantle-cell
lymphoma(38), non-small cell lung cancer(39), advanced gastric carcinoma(40), and
metastatic renal cancer(41) demonstrated similar results. However, in an additional
phase II study conducted in 34 patients with renal cell cancer, treatment with flavopiridol
resulted in 1 complete remission and 3 partial responses. An overall response rate of
12% was observed and 41% of patients achieved stable disease, i.e. no increase or
decrease in the extent of the cancer detected(42).
The majority of clinical studies using flavopiridol have used a dosing schedule of
72-hour continuous infusion once every 14 days. It appears that an alternative dosing
schedule of a 1-hour bolus per day, for three consecutive days, once every 3 weeks,
results in improved outcomes(43). In the clinical studies using the latter dosing schedule
41% - 71% of patients achieved stable disease(35;38;42), while only 0% - 28% of
patients treated with the former dosing schedule achieved stable disease(34;36;37;39-41).
Consequently, while initial clinical studies have shown only modest benefit, if any, to the
use of flavopiridol as a therapeutic agent for human malignancies, the results of changes
in dosing and scheduling are currently being investigated.
The clinical benefits of selective kinase inhibitors are not limited to the treatment
of human malignancies. When cells are stimulated by cytokines or growth factors,
signaling pathways initiated by the receptor activate the mammalian target of rapamycin
(mTOR) kinase. The mTOR kinase in turn phosphorylates and inactivates 4EBP, a
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binding protein that when active binds to the eukaryotic initiation factor 4E (eIF4E) and
inhibits translation. Thus, the mTOR kinase promotes translation by phosphorylating
4EBP. Rapamycin, also called sirolimus and Rapamune®, is a selective inhibitor of the
mTOR kinase. By so doing rapamycin inhibits T-lymphocyte activation and proliferation
in response to cytokines and also inhibits antibody production in plasma cells. These
properties make rapamycin an effective immunosuppressant, so much so that it is used as
a prophylactic therapy to prevent organ rejection in patients who have received kidney
transplants.
Imatinib mesylate and rapamycin represent two selective kinase inhibitors that
have been shown to posses clinical benefit. The clinical success of imatinib mesylate and
rapamycin suggests that selective kinase inhibitors may make effective treatments for
additional human diseases in which kinases play a regulatory role.

1.3. The PIM-1 Kinase
The PIM-1 kinase is a serine/threonine kinase(44-46) that has been shown to be
involved in the regulation of cell survival, differentiation, proliferation, and
tumorigenesis (for review see (47;48)). The PIM-1 kinase is the protein product of the
pim-1 gene, which was first identified as a preferential proviral insertion site of Moloney
Murine Leukemia Virus in virally induced T-cell lymphomas in mice(49). In humans.
pim-1 is expressed in normal lymphoid tissues (bone marrow, spleen, thymus, and lymph
node), testis, and circulating myeloid cells(50;51).
Although its specific role is not known, it is clear that the PIM-1 kinase is an
integral part of signal transduction pathways. Stimulation of the signal transducer and
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activator of transcription (STAT) proteins, STAT3 and STATS, result in expression of
the pim-1 gene. STAT3 and STATS are activated in response to cytokine and growth
factor stimulation; hence the cellular response to many cytokines and growth factors
involves the PIM-1 kinase. For example, it has been shown that the PIM-1 kinase is
involved in CD40 signaling in B cells(52), prolactin signaling(53), gpl30-mediated
STAT3 signaling(54), CD3 signaling(55), IFNy signaling(56), Jak-2-mediated signaling
through the erythropoeitin receptor(57), and cellular responses to IL-3(58-60) and GMCSF(60).
The substrates of the PIM-1 kinase that have been identified to date demonstrate
the involvement of the PIM-1 kinase in numerous cellular functions, including cell cycle
control, apoptosis, mitosis, transcription, and signal transduction (Figure 2). The specific
PIM-1 kinase substrates involved and the regulatory effects of PIM-1 kinase activity are
discussed in greater detail below. In short, the PIM-1 kinase phosphorylates key
regulatory proteins in each of the aforementioned cellular processes, thereby activating or
inactivating those key proteins and regulating the cellular machinery.
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PIM-1 Kinase

Apoptosis

Mitosis

CDC25A

BAD

NuMA

C-TAK1

PTP-U2S

Cell Cycle Control

Signal Transduction

Transcription

SOCS1

NFATcl

SOCS3

HP1

p2 Jcipl/wafl

Figure 2. PIM-1 kinase substrate proteins and the cellular mechanisms in which
they are involved. The substrates of the PIM-1 kinase that have been identified to date
reveal that the PIM-1 kinase is involved in the regulation of numerous cellular processes.
The PIM-1 substrate proteins are listed underneath the cellular process in which they are
involved.

The PIM-1 kinase participates in cell cycle control by helping to regulate the
Gl/S and the G2/M cell cycle checkpoints. In eukaryotic cells, the key regulatory
proteins involved in the Gl/S checkpoint are the Rb-repressor complex, cyclin-dependent
kinases 4/6 and 2 (cdk4/6, cdk2), and the protein phosphatase cdc25A. During the first
gap phase of the cell cycle, Gl, the Rb-repressor complex prevents progression into the
DNA synthesis phase (S) of the cell cycle. Cdc25A, when active, dephosphorylates
cdk4/6 and cdk2, thereby activating the kinases. The activated kinases phosphorylate Rb,
inactivating the repressor complex and permitting the transcription of genes coding for
additional proteins involved in the Gl/S progression and DNA replication. Thus,
activation of the protein phosphatase cdc25A is central to Gl/S progression. Mochizuki
et al demonstrated that the PIM-1 kinase phosphorylates cdc25A and thereby increases
the phosphatase activity of cdc25A(61). By so doing, the PIM-1 kinase promotes cell
cycle progression through the Gl/S checkpoint (see Figure 3).
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Figure 3. The PIM-1 kinase participation at the Gl/S checkpoint. The PIM-1 kinase
encourages cell cycle progression through the Gl/S checkpoint by phosphorylating and
activating cdc25A and inactivating p2lcipl/wafl. Arrows (
^ ) represent direct
activating modifications. Blunted lines (
1) represent direct inhibitory modifications.

The cell cycle inhibitor p2lcipl/wafl also participates in regulation of the Gl/S
checkpoint by inhibiting cdk2 activity, thereby discouraging Gl/S progression. Wang et
al have demonstrated that PIM-1 kinase phosphorylation of p2lcipl/wafl results in subcellular localization of p21cipl/wafl to the cytoplasm, inactivating the inhibitory effect of
p2icipi/wafi on

(see FjgUre 3) This represents a second mechanism by which the

PIM-1 kinase encourages cell cycle progression through the Gl/S checkpoint.
The PIM-1 kinase also promotes cell cycle progression through the G2/M
checkpoint. Progression from the G2 phase to the M phase of the cell cycle is regulated
by the activity of cdc25c phosphatase. During the G2 phase, cyclin-dependent kinase 1
(cdc2) is in a phosphorylated, inactive state. As the cell approaches the M phase of the
cell cycle cdc25c dephosphorylates cdc2, activating the kinase. Activated cdc2 in turn
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promotes the transcription of genes that drive the cell into the M phase of the cell cycle.
Cdc25c associated kinase 1 (C-TAK1) also regulates the G2/M transition by
phosphorylating and inhibiting cdc25c phosphatase, discouraging cellular progression
from G2 into M phase. Bachmann et al have demonstrated that the PIM-1 kinase
phosphorylates C-TAK1 and thereby inhibits C-TAK1 activity(62). Hence by inhibiting
the activity of C-TAK1, the PIM-1 kinase ultimately promotes cellular progression
through the G2/M checkpoint (see Figure 4).

C-TAKli \-

cdc25C

j

igdc2j

G2

Figure 4. The PIM-1 kinase participation at the G2/M checkpoint. The PIM-1
kinase encourages cell cycle progression through the G2/M checkpoint by
phosphorylating and inactivating C-TAK1, which ultimately leads to a phosphorylated,
active cyclin-dependent kinase 1 (cdc2). Arrows (
* ) represent direct activating
modifications. Blunted lines (
-1) represent direct inhibitory modifications.

In addition to promoting cell cycle progression from the G1 phase to the S phase
and from the G2 phase to the M phase of the cell cycle, the PIM-1 kinase participates in
mitosis by promoting formation of the mitotic spindle apparatus. The nuclear mitotic
apparatus protein (NuMA) is an essential part of the mitotic spindle. Bhattacharya et al
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have demonstrated that the PIM-1 kinase binds to and phosphorylates NuMA, forming a
complex that also contains heterochromatin protein ip (HP 1(3), dynein, and dynactin(63)
(see Figure 5). The PIM-1 kinase helps to stabilize this complex, which is necessary for
mitosis. It is evident, then, that the PIM-1 kinase is a major participant not only in cell
cycle control, but also in cellular division.
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Figure 5. Contribution of the PIM-1 kinase to the maintenance of a stable complex
between NuMA, dynein, dynactin and HP1|3. NuMA (blue) binds to dynein (beige)
and dynactin (orange) complexes that help to tether and align mitotic spindles (dotted
black lines). The PIM-1 kinase (red) interacts with HPlp (green) and NuMA (blue) to
bridge the chromosomal (gray) kinetochores with the spindle assembly complex.

The PIM-1 kinase also participates in the positive regulation of transcription via a
number of different mechanisms. Koike et al have demonstrated that the PIM-1 kinase
binds to and phosphorylates heterochromatin binding protein ly (HPly) and in so doing
significantly reduces the transcriptional repression function of HPly(64). Rainio et al
have demonstrated that the activity of the transcription factor NFATcl is enhanced by
PIM-1 kinase phosphorylation(65), and it is likely that PIM-1 phosphorylation of the
PIM-1 binding protein PAP-1 also regulates transcriptional activity(66). The PIM-1
kinase has also been shown to cooperate with the transcriptional coactivator p 100 to
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promote c-Myb transcriptional activity(67). Thus, the PIM-1 kinase has numerous
opportunities to regulate transcriptional activity.
The PIM-1 kinase also prevents cells from undergoing apoptosis by at least two
mechanisms. PTP-U2S is a tyrosine phosphatase that has been shown to enhance
differentiation and promote apoptosis. Wang et al have demonstrated that the PIM-1
kinase phosphorylates PTP-U2S, resulting in a decrease in phosphatase activity.
Moreover, they have shown that under phorbol myristic acid (PMA) stimulation the
human lymphoma cell line, U937, transfected with a dominant negative PIM-1 kinase
undergoes rapid differentiation and accelerated apoptosis. The opposite effect is
observed in U937 cells transfected with wild-type PIM-1 kinase(68).
The second mechanism by which the PIM-1 kinase regulates apoptosis is by
phosphorylation of the proapoptotic protein BAD(69;70). Under non-apoptotic
conditions the anti-apoptotic protein, Bcl-xL, interacts with the mitochondrial membrane
and prevents the release of cytochrome C. When unphosphorylated, BAD binds to BclxL, resulting in the release of cytochrome C from mitochondria and triggering apoptosis.
In contrast, phosphorylated BAD binds to the protein, 14-3-3, preventing its association
with Bcl-xL and keeping cytochrome C sequestered within mitochondria. Hence, the
PIM-1 kinase downregulates the mitochondrial-mediated apoptotic pathway by
phosphorylation of the pro-apoptotic protein BAD (see Figure 6).
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Apoptosis
Figure 6. The PIM-1 kinase is involved in regulating the mitochondrial mediated
apoptosis pathway. The PIM-1 kinase phosphorylates BAD, promoting binding of BAD
to 14-3-3. As a result, BAD does not bind to Bcl-xL, which would otherwise lead to the
release of cytochrome C from mitochondria and trigger apoptosis.
The PIM-1 kinase is also involved in regulating signal transduction pathways.
The janus kinases (JAKs) and signal transducer and activator of transcription (STAT)
proteins are also major regulatory proteins of signal transduction pathways, particularly
in the cellular response to cytokines (for review see (71)). Cytokine binding results in
receptor dimerization and activation of the associated JAKs. The JAKs in turn
phosphorylate STATs. The phosphorylated STATs dimerize and translocate into the
nucleus, where they bind to DNA responsive elements to induce the transcription of
target genes. Among the many target genes are genes coding for the PIM-1 kinase and
the suppressor of cytokine signaling (SOCS) family of proteins.
The SOCS family of proteins downregulate receptor signaling by inhibiting the
activity of JAKs. The PIM-1 kinase has been shown to phosphorylate and stabilize the
SOCS1 and SOCS3 proteins. By stabilizing SOCS proteins, the PIM-1 kinase reinforces

14

a negative feedback inhibition loop that helps to regulate the cellular response to cytokine
stimulation(72;73) (see Figure 7).

Figure 7. The PIM-1 kinase negatively regulates the JAK/STAT pathway. The
JAK/STAT pathway is activated in response to cytokine stimulation. As a result, STATs
initiate the transcription of several target genes, including those coding for the PIM-1
kinase and the SOCS family of proteins. The SOCS proteins participate in a negative
feedback inhibition loop by inhibiting the activity of JAKs. The PIM-1 kinase potentiates
this negative feedback loop by phosphorylation-mediated stabilization of the SOCS1 and
SOCS3 proteins.

Although the PIM-1 kinase is involved in numerous signaling events in normal
cells,knockout mice show no significant abnormalities, apart from erythrocyte
microcytosis. The very nearly normal phenotype of these mice is attributed to functional
compensation by other members of the PIM family of kinases, namely PIM-2 and PIM3(74). While the absence ofpim-1 showed minimal adverse effects in mice,
overexpression of pim-1 has been shown to have significant effects on cell survival. In
vitro studies reveal that enforced expression of pim-1 in the growth factor dependent
murine bone marrow cell line FDCP1 caused increased cellular proliferation, decreased
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apoptosis and cell death, increased cell survival(75), and protection from toxin-induced
cell death(76). Enforced expression of human pim-1 in FDCP1 cells also resulted in 1L-3
independent survival and clonogenic proliferation of cells(77). Moreover, pim-1 has
been shown to cooperate with both c-myc and N-myc in hematopoietic oncogenesis(51).
Furthermore, overexpression of pim-1 has been demonstrated in clinical cases of
lymphoma(78;79), leukemia(50) and prostate cancer(80;81).
While much is known about the PIM-1 kinase, it remains difficult to clearly
elucidate the specific cellular functions of PIM-1. To foster this process we have
endeavored to identify a selective inhibitor of the PIM-1 kinase. To date, there is no
known potent, selective antagonist of the PIM-1 kinase. The ability to selectively inhibit
PIM-1 activity would be an invaluable tool for the laboratory study of PIM-1 kinase
function. Additionally, such an inhibitor may serve as a template for the design of
molecular therapeutics for the treatment of diseases in which the PIM-1 kinase is
dysregulated.

1.4. Approaches in the Discovery and Design of Selective Kinase Inhibitors
A wide array of approaches has been used in the design of selective kinase
inhibitors. These approaches can broadly be divided into two types of methodologies computational and experimental. Computational approaches can be further subdivided
into ligand- and structure-based approaches. In this project we have employed
experimental, structure-based, and ligand-based approaches to discover and design a
selective inhibitor of the PIM-1 kinase, hence by way of introduction, we will discuss
each of these methodologies in further detail.
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Experimental approaches to the discovery of kinase inhibitors typically involve
the use of specifically designed assays to evaluate libraries of potential inhibitors. These
screening assays can be either biochemical or cellular in nature. The endpoint in such
assays is often a measure of binding affinity of the ligand to the kinase or a direct
measure of kinase activity itself, in the presence of the potential inhibitor.
Cellular screening assays typically make use of stable cell lines that yield a clear
target-specific result. The advantage of cell-based assays is that the target kinase is in a
cellular environment, presumably folded and behaving as it normally would within the
complete organism. The disadvantage is that, in the presence of inhibitor, apparent
alterations in the activity of the target kinase may in reality be due to modification of the
activities of an unintended target. This potential for what is called “off-target hits”
necessitates that positively identified inhibitors undergo further analyses to ensure that
they are indeed direct inhibitors of the target kinase.
A second drawback of cell-based assays is the potential toxicity of the compounds
tested. False positive hits can result from compounds that are toxic to the cells, resulting
in a diminished readout of the measured endpoint but no actual inhibition of the activity
of the target kinase. For a review of cell-based kinase assays see ref. (82).
In contrast to cellular assays, biochemical assays can be performed using high
concentrations of potential inhibitors without adverse effect, increasing the sensitivity of
the assay. Although the potential still exits for the inhibitor to interfere with the detection
reagents, careful and thorough controls can usually alleviate this problem without
difficulty. A second benefit of biochemical assays is that, unlike cell-based assays, there
is no potential for off-target hits. Furthermore, biochemical assays can be performed
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using smaller volumes than cell-based assays, an important advantage in high-throughput
screening experiments. For these reasons, biochemical assays tend to be preferred over
cell-based assays when screening for inhibitors of soluble kinases (for review see (83)).
Computational approaches, whether ligand-based or structure-based, involve the
development of a quantitative structure activity relationship (QSAR). A QSAR
quantitatively relates a measurable or calculable property of a molecule to its observed
biological activity. Computational approaches to inhibitor discovery and design use
QSARs to virtually screen potential inhibitors and predict their potency. In ligand-based
approaches the QSAR is developed based on the properties of a set of known inhibitors
of a target kinase. The structure of the target kinase is not a requirement for ligand-based
methodologies. Examples of ligand-based approaches are Comparative Molecular Field
Analysis (CoMFA)(84), the Pseudo Atomic Receptor Model (PARM)(85), the
Hypothetical Active Site Lattice (HASL)(86), and Comparative Molecular Similarity
Index Analysis (CoMSIA)(87).
In contrast to ligand-based approaches, structure-based approaches to inhibitor
design use three-dimensional information about the target kinase to predict the affinity or
potency of potential inhibitors (for review see (88)). The three-dimensional structure of
the target kinase is determined experimentally by x-ray crystallography or NMR
spectroscopy, or modeled theoretically by comparative modeling.
The discovery and design of selective inhibitors does not require the use of one
approach exclusively. Recently Card et al have reported success in the discovery and
design a family of phosphodiesterase inhibitors using a well coordinated combination of
experimental and computational methods(89).
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1.5. Types of Selective Kinase Inhibitors
Kinases, as a family of enzymes, share a structurally similar catalytic core. The
core consists of two domains, an N-terminal domain and a C-terminal domain, connected
by a short hinge region. Typically the N-terminal domain is smaller the smaller of the
two and made up of mostly p-sheets, while the larger C-terminal domain contains mostly
a-helices. The hinge region allows for some flexibility in the position of the N- and Cterminal domains relative to each other and serves as one border of the ATP-binding site.
The inferior region of the N-terminal domain and the superior region of the C-terminal
domain form additional borders for the ATP-binding site. Commonalities exist even in
the primary structure of kinases, where amino acid residues with similar properties are
found in key positions in the catalytic core. As an example the structure of cAMPdependent kinase, with bound ATP, is pictured below. Taylor and Radzio-Andzelm have
published an enlightening and useful review of the common motif of protein kinases(90).
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Figure 8. The General Structure of the Catalytic Core of a Kinase. Kinases typically
consist of an N- (blue) and C-terminal (red) domain connected by a short hinge region
(green). ATP (yellow) is shown bound in the ATP-binding site, which is formed by the
hinge region and sections of both the N- and C-terminal domains. Mg2+ (pink) or Mn2+ is
also required for activity. Pictured above is cAMP-dependent protein kinase (PKA; PDB
id 1ATP).
In the development of selective kinase inhibitors one can target a number of
different regions of the kinase. The catalytic domain of a typical kinase contains at least
two binding pockets - an ATP-binding pocket and a substrate-binding pocket. Many
kinases also contain one or more protein-binding domains, where regulatory proteins
interact with and influence the activity of the kinase. Selective kinase inhibitors are often
directed at the ATP-binding site, the substrate-binding site, or a regulatory protein
binding site of a kinase.
Pseudo-substrate inhibitors are often developed to target the substrate-binding site
of a kinase. They are usually designed as peptides or peptidomimetics having similar
molecular features to a true substrate, but lacking the ability to be phosphorylated. When
pseudo-substrates bind to their target kinase they occupy the substrate-binding site but are
20

not phosphorylated by the kinase. The result is an inability of the target kinase to
phosphorylate its true substrates.
There are many examples documenting the successful use of pseudosubstrate
peptides to inhibit key kinases in signal transduction pathways. Extracellular signalregulated kinase (ERK) is a mitogen-activated protein kinase (MAPK). ERK is activated
when it associates with and is phosphorylated by MAPK kinase (MEK). A cellpermeable MEK1-derived peptide, however, successfully inhibited ERK activation in
vitro and in vivo. Additionally, the peptide was able to inhibit ERK-mediated activation
of the transcriptional activity of ELK1. Furthermore, the selectivity of the peptide was
demonstrated by its inability to inhibit MAPKs similar to ERK, namely c-Jun aminoterminal kinase (INK) and p38 protein kinase (p38)(91).
Another example is PK1, a 20 amino acid pseudo-substrate peptide of the cAMPdependent protein kinase (PKA). PK1 has been shown to be an extremely potent and
effective inhibitor of PKA in laboratory studies(92-94). Additionally, a substrate peptide
of casein kinase 2 (CK2) has also been described. The peptide was shown to abrogate
CK2 phosphorylation, induce apoptosis in a variety of cancer cell lines, and cause
substantial regression of solid tumors in mice(95).
Although pseudo-substrate inhibitors have been shown to be effective antagonists
of kinase activity in vitro and have been shown to affect kinase activity in mammalian
cells there has been little success in translating the effectiveness of these inhibitors to the
clinic (for review see (96;97)). Kinase inhibitors that bind to a regulatory protein-binding
site of the target kinase have also lacked clinical efficacy(98).
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Small molecule antagonists of ATP-binding have perhaps been the most
successful class of kinase inhibitors. These inhibitors preclude ATP-binding to a kinase
by interacting with the ATP-binding pocket of the kinase and thereby preventing
phosphorylation of the substrate protein. However, because all kinases have an ATPbinding pocket, an ATP antagonist could potentially interact with any kinase. It follows
then, that the major potential drawback of ATP-competitive inhibitors is selectivity.
Davies et al demonstrated the reality of this problem by revealing that many ATPcompetitive inhibitors that were thought to be selective actually affect the activity of
more than one kinase(99).
Imatinib mesylate, for example, was discussed previously as an ATP-competitive
inhibitor of the BCR-ABL kinase and as such is an effective molecular therapeutic for
CML. However, imatinib mesylate also inhibits the activity of the platelet-derived
growth factor (PDGF) receptor kinase and the stem cell factor (SCF) receptor kinase, ckit. Moreover, imatinib mesylate is such an effective inhibitor of c-kit that it is also
indicated for the treatment of patients with c-kit positive GIST.
The ATP-binding sites of protein kinases are highly conserved, yet despite the
fact that the human kinome is thought to contain more than 500 kinases(15; 100), imatinib
mesylate has only been reported to be an effective inhibitor of three kinases. This
selectivity of imatinib mesylate illustrates the fact that there is enough diversity among
the ATP-binding sites of kinases to allow for inhibitor discrimination. While it may be
difficult to develop ATP-competitive inhibitors that will affect one kinase exclusively, it
is certainly possible to develop inhibitors that possess a favorable selectivity profile (for

22

review see (15)). Such inhibitors can and have become effective treatments for human
diseases.
It is the goal of this project to identify a selective inhibitor of the PIM-1 kinase.
We hypothesize that such an inhibitor will serve as a valuable tool for the laboratory
study of PIM-1 kinase activity and may serve as a template for the design of molecular
therapeutics for the treatment of diseases in which the PIM-1 kinase is dysregulated. In
this project we have employed experimental and computational approaches to identify a
potent, selective inhibitor of the PIM-1 kinase.
The project consisted of three specific aims. The first specific aim was to develop
an efficient kinase assay for the evaluation of potential PIM-1 kinase inhibitors. Our
second specific aim was to identify a lead compound inhibitor of the PIM-1 kinase. The
third and final specific aim was to determine the effect of the lead PIM-1 kinase inhibitor
compound on mammalian cells.

1.6. Development of an Efficient Kinase Assay for the Evaluation of Potential
PIM-1 Kinase Inhibitors (Specific Aim 1)
The ability to assess the potency of potential PIM-1 kinase inhibitors was a
fundamental necessity for the success of this project. Consequently, our first specific aim
was to develop an efficient kinase assay to evaluate potential PIM-1 kinase inhibitors.
We sought to develop an assay that would allow for the simultaneous evaluation of
several inhibitors in a manner that produces accurate, reproducible, and easily
quantifiable data.
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1.7. Identification of a Lead Inhibitor Compound of the PIM-1 Kinase (Specific
Aim 2)
To identify a lead inhibitor compound of the PIM-1 kinase we have employed
phage display techniques, computational design, and library screening. Each of these
techniques has been shown to be an effective method of identifying potent inhibitors of
enzyme activity. The assay that we developed in specific aim 1 allowed us to test
potential PIM-1 kinase inhibitors in an effort to identify a lead compound. We identified
such a compound because of its properties as a potent, selective antagonist of PIM-1
kinase activity.

1.8. Determine the Effect of the Lead PIM-1 Kinase Inhibitor Compound on
Mammalian Cells (Specific Aim 3)
The third and last specific aim of this project was to determine the effect of the
lead PIM-1 kinase inhibitor compound on mammalian cells. Our goal was that in
addition to inhibiting PIM-1 kinase activity in vitro, the compound would also inhibit
PIM-1 kinase activity in a mammalian cellular environment. This property would allow
us to examine the effects of PIM-1 kinase inhibition on cellular properties such as
survival and proliferation.
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CHAPTER TWO
METHODS
2.1. Development of an Efficient Kinase Assay for the Evaluation of Potential PIM1 Kinase Inhibitors (Specific Aim 1)
2.1. E Immunoblot-based Assay
A. Reagents
i. Production and purification of recombinant GST-PIM-1 kinase and GST-BAD
Throughout the course of this project we used recombinant, active PIM-1 kinase
that contained a glutathione-S-transferase (GST) tag for ease of purification. We also
used recombinant GST-BAD as a substrate in PIM-1 kinase activity assays. Production
of recombinant GST-PIM-1 kinase and GST-BAD proteins has been described
previously(70). Briefly, cDNAs for human PIM-1 and BAD in bacterial expression
plasmids pGEX2T and pGEX4T respectively were used to transform BL21 E. coli cells
(Novagen). Cultures were grown from ampicillin selected transformants and expression
of the recombinant protein induced by overnight induction with 0.5 mM isopropyl-betaD-thiogalactopyranoside (IPTG). The recombinant proteins were isolated from cell
lysate by incubation with glutathione agarose beads (Sigma). Purified protein was then
eluted from the beads using a 20 mM glutathione solution and subsequently dialyzed
overnight against a Hepes buffered solution (136 mM NaCi, 2.6 mM KC1, 20 mM
HEPES). The purified proteins were then aliquoted and stored at -80°C until used.
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B. Technique
i. Kinase assays
In vitro kinase assays were performed in microcentrifuge tubes in a total volume
of 30 pi. A master mix consisting of 2X kinase buffer (40 mM MOPS, 25 mM MgCl, 2
mM MnCl, 2 mM EOT A, 300 mM NaCl, 20 pM ATP, 2mM DTT, and 10 mM £glycerophosphate) and 125 ng/pl GST-BAD (as kinase substrate), was distributed in
equal 16 pi volumes to each tube. The desired amount of inhibitor (dissolved in 1%
DMSO) was added to each tube with additional 1% DMSO subsequently added such that
the final volume of added 1% DMSO was equal to 10 pi. The reaction was initiated by
the addition of 3.6 ng GST-PIM-1 in a total volume of 4 pi. The tubes were incubated in
a 30°C water bath for 1 hour to allow the kinase reaction to proceed and the reaction was
terminated by the addition of 8 pi 5X SDS loading buffer.

ii. Immunobloting
At the conclusion of the kinase assay, twenty microliters of the kinase reaction
mixture was boiled for 4 minutes in SDS loading buffer and subsequently loaded into a
12% polyacrylamide gel for SDS-PAGE. The proteins were then transferred to a
polyvinylidene fluoride (PVDF) membrane (Millipore) and the membrane blocked for 1
hour at room temperature with TBS containing 5% BSA and 0.1% Tween-20. The
membrane was incubated overnight at 4°C with a monoclonal anti phospho-BAD serine
112 antibody (Cell Signaling) in a 1:2000 dilution. The next day the membrane was
washed for 30 minutes in TBST with 3 buffer changes. Then the membrane was
incubated with a secondary horseradish peroxidase conjugated goat anti-mouse antibody
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(Pierce) in a 1:20,000 dilution for 1 hour at room temperature. After 30 minutes of
washing with TEST the membrane was treated with chemiluminescent reagent (Pierce),
exposed to x-ray film, and the film was subsequently developed.

C. Analysis
The intensity of the bands on the x-ray film is representative of the amount of
phosphorylated product present. We used densitometry to quantify the intensity of the
bands.

2.1.2. ELISA-based Assay (Solid Phase)
A. Reagents
Recombinant GST-PIM-1 and GST-BAD were purified as described above (see
section 2.1.1. A).

B. Technique
The ELISA-based kinase assay was used in both the computational drug design
approach and the functional assay approach to identify a PIM-1 kinase antagonist. The
assay was a fundamental source of data for both approaches.
The ELISA-based kinase assay was developed mainly to facilitate efficient
screening of a small molecule inhibitor library and was based on our demonstration that
the PIM-1 kinase is a potent kinase for phosphorylating BAD on serine-112(70). Prior to
the development of the ELISA-based kinase assay, we used an in vitro kinase assay
performed in microcentrifuge tubes followed by immunoblot analysis to detect the
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presence of phosphorylated kinase substrate. This method was described above (see
section 2.I.I.B.2.).
With the knowledge that the completion of this project would necessitate the
screening of over a thousand compounds for inhibitory potency against the PIM-1 kinase,
it was clear that the Immunoblot-based assay would be an inadequate methodology.
The development of the ELISA-based kinase assay was an iterative process.
Through repeated use we developed ways to enhance the assay and incorporated
beneficial changes into the protocol. Consequently there are some differences between
the assay used in the early part of the project (solid phase) and the assay used towards the
end of the project (liquid phase). The ELISA-based kinase assay we developed is
described below, along with pertinent changes that were incorporated into the protocol
during the course of this project.
To begin the ELISA-based kinase assay ninety-six-well flat bottom plates
(Coming) were coated overnight at 4°C with recombinant GST-BAD (Ipg/well in
HEPES buffer [136 mM NaCl, 2.6 mM KC1, 20 mM HEPES]). After coating, the plates
were blocked for 1 hour at room temperature with 10 mg/ml BSA in HEPES buffer. The
BSA coating solution was then removed and 5 jal of each inhibitor, dissolved in 50%
DMSO, was added to each well to obtain a final concentration of approximately 10 pM.
Then 100 pi of kinase buffer (20 mM MOPS, 12.5 mM MgC^, 1 mM MnCh, 1 mM
EGTA, 150 mM NaCl, 10 pM ATP, ImM DTT, and 5 mM p-glycerophosphate)
containing 25 ng recombinant GST-PIM-1 kinase was added to each well. The kinase
buffer was pre-warmed to the reaction temperature of 30°C, and the plate was placed on a
gel slab dryer pre-warmed to 30°C. The reaction was stopped after 60 minutes by
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removal of the reaction buffer followed by addition of 100 |al of HEPES buffer
containing 20 mM EDTA to each well. The plates were then washed thoroughly with
HEPES buffer containing 5 mM EDTA and then finally HEPES buffer without EDTA.
Phosphorylated GST-BAD was then detected with a monoclonal anti-phosphoBAD
(serine 112) antibody (Cell Signaling), incubated for 1 hour at 37°C. The plates were
then washed thoroughly with HEPES buffer containing 0.1% NP-40 and then HEPES
buffer without NP-40. Finally, a secondary goat anti-mouse IgG-peroxidase conjugated
antibody (Pierce) was added to each well and incubated for 30 minutes at room
temperature. Following washing with HEPES buffer containing 0.1% NP-40 and then
HEPES buffer without NP-40, immune complexes were detected with Turbo-TMB
peroxidase substrate (Pierce). The level of phosphorylated GST-BAD present was
proportional to the absorbance measured at 450 nm. For a graphical representation of
summary of the assay protocol see Figure 9 below.
When determining IC50 values of PIM-1 kinase inhibitors we modified the above
assay by reducing the kinase and TMB reaction times to 3 - 6 and 10 minutes,
respectively, in order to ensure a linear reaction velocity. The concentration of each
inhibitor was varied from 0.001 pM to 300 pM while the concentration of ATP was kept
constant at 10 pM. All of the kinase reactions to determine IC50 values used a single
preparation of GST-PIM-1 and GST-BAD at a constant concentration.
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Figure 9. ELISA-based kinase assay (solid phase). Pictured above is a graphical
representation of the ELISA-based kinase assay (solid phase). The assay is described in
detail in the text.

C. Analysis
Sigmoidal dose response nonlinear regression analyses using a single binding site
model were performed using GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com.

2.1.3. ELISA-based Assay (Liquid Phase)
In the kinase assays to determine the IC50 of quercetagetin for the alternative
BAD serine 112 kinases (RSK2, PIM-2, and PKA), a biotin-BAD peptide substrate was

30

used instead of recombinant GST-BAD. Use of the biotin-BAD substrate allowed the
kinase reaction to be performed with both the kinase and substrate in the liquid phase of
the reaction, rather than having the substrate immobilized to the bottom of the plate.

A. Reagents
i. Recombinant GST-PIM-1
Recombinant GST-PIM-1 was produced and purified as described above (see
section 2.1.1. A).
ii. Biotin-BAD peptide
The sequence of the BAD peptide (GGAGAVEIRSRHSSYPAGTE) was
generated from residues 62-81 of human BAD (accession # AAH01901). This region
of human BAD is homologous to the region surrounding serine 112 of murine BAD. The
BAD peptide was synthesized with a biotin tag to facilitate binding of the peptide to the
streptavidin-coated plate.
B. Technique
Each reaction was initiated by the addition of biotin-BAD peptide to the kinase
buffer. The reaction was allowed to continue for five minutes in a 30°C water bath and
was terminated by transferring the reaction mixture to a streptavidin-coated plate
containing 100 pi of 40 mM EDTA. The phosphorylated peptide was allowed to bind to
the plate at room temperature for 10 minutes and then the level of phosphorylation was
determined by ELISA as described above (see section 2.1.2.B.). The technique is
illustrated in Figure 10).
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Figure 10. ELISA-based kinase assay (liquid phase). Pictured above is a graphical
representation of the ELISA-based kinase assay (liquid phase). The assay is described in
detail in the text.

C. Analysis
As with the solid phase ELISA-based kinase assay, sigmoidal dose response
nonlinear regression analyses using a single binding site model were performed using
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego California
USA, www. graphpad.com.
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2.2. Identification of a Lead Compound for a PIM-1 Kinase Inhibitor
(Specific Aim 2)
2.2.1. Phage Display
Wc used phage display techniques to identify a pseudo-substrate peptide that
binds to the PIM-1 kinase. Phage display is a selection technique where a peptide or
protein is “displayed” on the surface of a bacteriophage by genetic fusion with one of the
virion coat proteins. The selection process is performed by a procedure called
panning(10l;102). In panning, the target protein (such as an enzyme or receptor) is
immobilized to a plate or bead. The phage library is incubated with the immobilized
target, then unbound phage are washed away and bound phage are subsequently eluted.
Typically 3-4 rounds of panning are performed to select for bacteriophage displaying
peptides that bind to the target protein.
A. Reagents
i. GST-PIM-1
Recombinant GST-PIM-1 was produced in purified as described above (see
section 2.1.1.A).

ii. PhD-12 phage display peptide library
We utilized the Ph.D.-12 phage library displaying random dodecapeptides fused
to the minor coat protein (pill) of M13 phage. Random peptide libraries have been used
successfully for numerous purposes(103; 104), including the identification of substrate
sequences for proteases(105-107) and kinases(95; 108-110). The Ph.D.-12 Phage Display
Peptide Library Kit was purchased from New England Biolabs.
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iii. HGVKKRPHNPYG (HGV) Peptide
The HGV peptide was synthesized by Peptron, Inc., and received lyophilized.
Subsequently we made a 1 mg/mL stock solution of HGV peptide dissolved in 1%
DMSO. The stock solution was aliquoted and stored at -20°C until use.

B. Technique
i. Biopanning
The Ph.D.-12 Phage Display Peptide Library Kit (New England Biolabs) was
used to identify peptide ligands of the PIM-1 kinase. The Ph.D.-12 phage library is a
Ml3 filamentous phage library expressing random dodecapeptides fused to pill, a minor
virion coat protein. The majority of the experiment was conducted according to the
manufacturer’s protocol. Changes to the manufacturer’s protocol are detailed below.
Six-centimeter polystyrene plates (Coming) were coated overnight with 1.5 mL
coating solution (0.1 M NaHCCE (pH 8.6)) containing 150 pg of GST or GST-PIM-1 at 4
°C. Subsequently, the coating solution was poured off and the plate filled completely
with blocking solution (0.1 M NaHCOs (pH 8.6), 5 mg/ml BSA, 0.02% NaNs). Blocking
was performed for a minimum of 1 hour at 4°C. Immediately before adding phage the
blocking buffer was removed from each plate and the plate was washed six times with
TBST (TBS + 0.1% Tween-20). For the first round of biopanning 1 mL TEST
containing 1.5 x 1011 phage was pre-adsorbed against GST for 30 minutes at room
temperature to remove GST-binding phage. Subsequently, the non-binding phage were
removed from the GST-coated plate and used to biopan against GST-PIM-1 for 60
minutes. The phage were poured off and the GST-PIM-1 plate washed 10 times with
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TBST to remove non-binding phage. Bound phage were eluted by incubation for 10
minutes with 1 mL 0.2M Glycine-HCl (pH 2.2) containing 1 mg/ml BSA. The eluate
was then transferred from the plate to a microcentrifuge tube and the pH neutralized by
the addition of 170 pi 1M Tris pH 8.0. The phage were stored overnight at 4°C. See
Figure 11 below for an overview of the biopanning procedure.

• GST
GST-PIM-1

Figure 11. Biopanning Protocol. Each round of biopanning consisted of an initial step
of pre-adsorbing the phage to a GST-coated plate to remove GST-binding phage. The
phage that did not bind to GST where then panned against GST-PIM-1. After washing
away non-binding phage, PIM-1 binding phage were eluted and amplified. A total of 4
rounds of biopanning were performed. After the 4th round of biopanning, DNA was
extracted from the PIM-1 binding phage and sequenced. The peptide displayed by each
phage was determined from its DNA sequence.

The next day the eluate was amplified by addition to a 20 mL overnight culture of
Xl Blue E. coli cells (Stratagene). The culture was incubated at 37°C with vigorous
shaking in LB media containing 20 pg/ml tetracycline for 4.5 hours. The culture was
then transferred to a centrifuge tube and centrifuged at 4°C for 10 minutes at 10,000 rpm
to pellet the bacteria. The supernatant was transferred to a fresh tube and centrifuged
again as above. This supernatant was again transferred to a new tube and 10% w/v PEG
added to precipitate phage. Precipitation was allowed to occur overnight at 4°C.
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The next day the eluate was centrifuged at 10,000 rpm and 4°C for 15 minutes.
The pellet was resuspended in 1 mL TBS, transferred to a new tube and re-centrifuged for
5 minutes to pellet residual cells. The supernatant was transferred to another fresh tube
and re-precipitated by the addition of 10% w/v PEG. The precipitation was performed
for 60 minutes on ice and then centrifuged for 10 minutes. The supernatant was
discarded and the pellet resuspended in 200 pi TBS containing 0.02% NaNs. One final
centrifugation was performed to remove any remaining insoluble matter, and the
supernatant transferred to a new tube. This represents the amplified phage from the first
round of biopanning.
The eluate was then tittered according to the manufacturer’s protocol. Five mL of
LB was inoculated with Xl Blue cells and incubated until the mid-log phage of growth
was reached (ODeoo ~ 0.5). During this time top agarose (10 g/L Bacto-Tryptone, 5 g/L
yeast extract, 5 g/L NaCl, 1 g/L MgC^-bLLO, 7 g/L agarose) was melted and dispensed
into sterile culture tubes in 3 mL aliquots, 1 tube for each expected phage dilution. The
tubes were kept at 45°C until used to prevent premature solidifying.
Ten-fold serial dilutions of eluate were prepared in LB medium (101 - 104) and
the bacterial culture dispensed into microcentrifuge tubes, 200 pi for each phage dilution.
Ten pi of each phage dilution was added to 200 pi of bacterial culture, vortexed quickly,
and incubated at room temperature for 1 - 5 minutes. The infected cells were then added
to top agarose, vortexed quickly, and immediately poured onto a pre-warmed (37°C) LB
plate. The agarose was allowed to solidify, then the plate was inverted and incubated
overnight at 37°C. The next day the titer of the eluate was determined by multiplying the
number of plaques on the plate by the appropriate dilution factor to yield plaque forming
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units (pfii) per 10 pi. The titer of the amplified phage from the 1st round of biopanning
(BP1 phage) was determined to be 4.3 x 106 pfu/pl.
The second round of panning was performed similarly to the first. A total of 8.17
x 10 8 BP 1 phage were used as input phage for the second round of panning and the
washing steps were perfonned with TBST containing 0.5% Tween. The titer of the
amplified phage from the 2nd round of panning (BP2 phage) was determined to be 5 x
1010 pfu/pl.
In the 3ld round of panning 2.5 x 1011 BP2 phage were used as input phage. The
3rd round of panning was performed similarly to the 2nd round of panning, without
amplifying the eluate. The titer of the unamplified eluate from the 3rd round of
biopanning (BP3 phage) was determined to be 1.6 x 104 pfu/pl.
For the proof of enrichment experiment two pannings were performed in parallel
using 1.5 x 106 Ph.D.-12 (the original library) phage and 1.6 xlO6 BP3 phage as the input
phage. One round of panning was performed for each of the original Ph.D.-12 library
phage and the BP3 phage by first pre-adsorbing the phage against GST, and then panning
the unbound phage against GST-PIM-1. The titer of the unamplified phage was
determined as described above.
The panning of the BP3 phage for the proof of enrichment experiment represents
a 4th round of panning, hence we have designated the eluted phage from this experiment
BP4 phage. To determine the peptide sequences that were displayed by the P1M-1
binding phage, we sequenced the DNA of isolated phage from random colonies on the
BP4 phage titer plate. We were unable to extract DNA of adequate quantity and quality
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for sequencing from the phage using the manufacturer’s protocol, consequently the
following protocol was employed.
Phage from 10 random colonies were used to inoculate 10 mL of LB containing
20 pg/mL tetracycline and 200 pi Xl Blue cells (OD ~ 0.5). The cells were cultured
overnight at 37°C. The next day the cells were centrifuged at 6,000 rpm for 10 minutes.
Twenty percent w/v PEG 8,000 and 0.2 volumes 2.5M NaCl was added to the
supernatant and the phage were incubated for 1 hour. The phage were then centrifuged
for 15 minutes at 11,500 rpm. The supernatant was removed and the pellet resuspended
in 200 pi TE buffer (pH 8.0). One hundred microliters of a phenoECHCbiisoamyl
alcohol (25:24:1) solution was added to the phage and mixed by vortexing. The phage
were then incubated at room temperature for 5 minutes, vortexed, and centrifuged again
for 5 minutes. The top 175 pi was transferred to a new microcentrifuge tube, to which 20
pi 3M sodium acetate (pH 5.2) and 400 pi 95% ethanol were added. The DNA was
precipitated for one hour at -20°C, centrifuged, and the pellet washed with -20°C 70%
ethanol. Lastly, the DNA pellet was allowed to air-dry and subsequently resuspended in
50 pi TE buffer (pH 8.0).

ii. Cellular uptake studies
To encourage cellular uptake of the HGV peptide we formed non-covalent stable
complexes of HGV with a cell membrane permeabilizing HIV-TAT derived peptide. The
peptide complexes were formed using protein-protein association domains consisting of a
hydrophobic core surrounded by charged amino acids (see Figure 12). The first peptide
was a FITC-conjugated HGV peptide with the protein-protein association domain,
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glutamate-leucine-isoleucine-valine-aspartate (ELIVD), present at the C-terminus (FITCHGVKKRPHNPYG-ELIVD). The second peptide was an HIV-TAT peptide with a
complimentary protein-protein association domain, lysine-valine-isoleucine-leucinelysine (KVILK), present at the N-terminus (KVILK-TAT). The third peptide was similar
to the second, but contained 2 KVILK domains (KVILKVILK-TAT). Each peptide was
synthesized by Peptron, Inc.

ELIVD
#

H

H

H

#

•

H

H

H

+

KVILK

Figure 12. Protein association domains used to form peptide complexes. Association
domains were included in the synthetic peptides to encourage complex formation in
aqueous solution. The top domain, ELIVD (glutamate-leucine-isoleucine-valineaspartate), consists of a core of hydrophobic amino acids flanked by negatively charged
amino acids. The bottom domain, KVILK (lysine-valine-isoleucine-leucine-lysine),
consists of a core of hydrophobic amino acid residues flanked by positively charged
residues. In an aqueous solution the hydrophobic residues interact with each other. The
attractive forces of the oppositely charged flanking residues reinforce this interaction.
Green circles, labeled “H”, represent hydrophobic amino acids. Blue circles, labeled
represent negative charges and red circles, labeled “+”, represent positive charges.
To perform the cellular uptake experiments, 15 pg of KVILK-TAT or
KVILKVILK-TAT was incubated with 45, 90, and 135 pg of FITC-HGVKKRPHNPYGELIVD peptide for 30 minutes in PBS to allow complexes to form. The complexes were
then incubated with growing U20s cells (an adherent human osteosarcoma cell line) for 6
hours.
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C. Analysis
i. Phage display
The sequences of the peptides displayed by the PIM-1 kinase binding phage were
determined by sequencing the DNA of individual clones. The DNA was sequenced using
the primers provided in the Ph.D.-12 Phage Display Library Kit.

ii. Cellular uptake studies
Subsequent to incubation with HGV-TAT complexes, the U20s cells were washed
thoroughly, trypsinized, and analyzed by flow cytometry to detect intracellular peptides.
A separate population of cells was washed thoroughly, fixed, and the nuclei
counterstained with DAPI. The presence of intracellular FITC-HGVKKRPHNPYGELIVD was then assessed by fluorescence microscopy.

2.2.2. Computational Design of a Novel PIM-1 Kinase Inhibitor
Structure-based drug design is a proven method for accelerating the process of
drug discovery and development (for review see (111)). For this purpose a threedimensional structure of the target enzyme or receptor is often accessible in the form of a
crystal structure of the target protein. However an experimental structure of the target
protein is not always available, such as during the early stages of a drug discovery effort
or when the target protein is difficult to crystallize. When the crystal structure of a
homologous protein or one with similar amino acid sequence is available, comparative
modeling can generate a structural model for use in structure-based drug design. Such
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models have been used successfully to screen in silico libraries of potential
inhibitors( 112-115) and in the de novo design of lead inhibitors of kinases( 116; 117).
In our structure-based design efforts a crystal structure of the PIM-1 kinase would
have been an ideal resource, however, at the outset of this project there were no published
crystal structures of the PIM-1 kinase available. Consequently, we constructed an in
silico three-dimensional model of the PIM-1 kinase using comparative modeling
techniques.
Homology modeling (or comparative modeling) is a computational technique by
which the three-dimensional structure for a protein of unknown structure is modeled
using the known structure of a homologous protein as a template(l 18). This technique
has emerged has a powerful method for determining the tertiary structure of proteins that
have not yet been crystallized. More specifically, homology modeling methods for
protein kinases have been described and successfully employed(l 19).
We also performed affinity docking of potential PIM-1 kinase inhibitors to the
PIM-1 kinase model. Affinity docking is a computational technique whereby a ligand is
“docked” into the binding pocket of its receptor molecule. The “goodness of fit” of the
ligand into the binding pocket is then determined by computational measures of the
intermolecular interactions (usually non-bonding electrostatic and Van der Waals forces)
and reported as a docking score. The docking scores can be used to create a quantitative
structure-activity relationship (QSAR) where the scores are subsequently correlated with
known experimental measures of binding (such as Ki or IC50) for a training set of ligands.
If the correlation is strong, then the affinity docking can be used with confidence to
predict the IC50 or Kj of new ligands for which there are no experimental data. We
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employed this approach using the model of the PIM-1 kinase and a set of flavonoid
inhibitors for which we have determined experimental IC50 values.
Affinity docking is a structure-based approach to inhibitor design. We also
employed a ligand-based approach termed Comparative Molecular Field Analysis
(CoMFA). CoMFA is a three-dimensional quantitative structure activity relationship
(QSAR) methodology. The analysis correlates, using an iterative approach, electrostatic
and steric differences with biological activity, identifying potentially important
relationships. The validated model can be used for the design of novel ligands and to
predict the functional activity of those ligands before synthesis.
In addition to its successful use to evaluate the properties of the binding sites of
kinase-specific inhibitors(120-122), the CoMFA methodology has shown utility in
evaluating the ligand binding sites of numerous receptors(123-138), calcium
channels(139), chromosome p450 enzymes(140-144), human immunodeficiency virus-1
integrase(145), and p-tubulin(146). In each case the CoMFA models demonstrated a
strong correlation between predicted and experimental ligand activity.
A. Reagents
Homology modeling was performed using the HOMOLOGY module of Insightll
and docking studies were conducted using the AFFINITY module of Insightll.
Comparative Molecular Field Analysis (CoMFA) was performed using SYBYL (Tripos,
Inc.)
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B. Technique
i. Homology modeling
Using the protein sequence of the PIM-1 kinase (accession # XP 043451), we
performed a FASTA(147) search within Insightll (Accelrys, San Diego, CA) to screen
the Protein Databank (PDB, www.rcsb.org) for potential template structures. The
sequence of Death-associated Protein Kinase (DAPK) was determined to be the most
similar to that of the PIM-1 kinase and as such was chosen as the primary template upon
which to model the structure of PIM-1.
The structure of DAPK with bound ATP analogue, AMPPNP (PBD file
1 JKK.pdb), was used as the template structure for the modeling process. The alignment
generated by PASTA was used without modification when insertions or deletions were
placed within loops; otherwise the alignment was modified to place an insertion or
deletion within the nearest loop in the DAPK structure. The structurally conserved
regions (SCRs) were chosen to include complete elements of secondary structure and
highly conserved loop sequences. The assignment of coordinates for backbone and
conserved side-chain atoms was taken directly from the template structure. The
coordinates for mutated side-chain residues were automatically assigned by the
Homology module of Insightll (Accelrys, Inc., San Diego, CA).
Our alignment of the PIM-1 sequence with DAPK indicated that there were
deletions in the PIM-1 sequence N- and C- terminal to the G-helix, when compared to
DAPK. In order to improve our model in this region, we used cAMP-dependent kinase
(PDB file lATP.pdb) as an alternate template for the G-helix of PIM-1 and the flanking
coil regions. The coordinates of the flanking F-helix (residues 216 to 230) and H-helix
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(residues 246 to 258) of DAPK were superimposed on the coordinates of the F-helix
(residues 238 to 252) and H-helix (residues 264 to 276) of cAMP-dependent kinase
(PKA). The resulting root mean squared deviation (RMSD) of the distance between the
superimposed alpha carbon atoms was 0.70 A, suggesting that the relative orientation of
the F and H helices is similar in DAPK to that of PKA. Our alignment models the six
residue deletion in the PIM-1 sequence after the F-helix (relative to DAPK and PKA) by
shortening the G-helix by one and a half turns. The four-residue deletion between the G
and H helices in PIM-1 relative to DAPK is conserved in PKA and was modeled using
1ATP as an alternative template to 1JKK.
In the cases where PIM-1 loop sequences contained differing numbers of residues
than the template kinase structure or contained very different amino acid sequences, the
loop structures were randomly generated. When selecting a randomly generated loop
structure we looked for conformations that minimized the solvent exposure of
hydrophobic side chains. The selected loop structures were then refined to remove steric
overlap by energy minimizing the conformation of the loop while holding the coordinates
of atoms in SCRs constant.
We examined the structure at this point and identified steric overlaps of greater
than 0.2 A between atoms in our model. Where possible, we removed these overlaps by
selecting alternate rotamer conformations(148) of the side chains in loop or mutated SCR
residues. The conformation of the side chain was then energy minimized while holding
constant the coordinates of all other residues. Wherever possible the side chain
conformations of conserved residues within SCRs were not altered.
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ii. Docking
The structures of the inhibitors used for docking were constructed using the
Builder module of Insightll (Accelrys, San Diego, CA), and were computationally
docked into our PIM-1 models using the AFFINITY module of Insightll and the CFF
forcefield. Due to steric hindrances within the binding site, the B ring of the flavonoids
could not rotate a full 360° during the docking calculations. Hence, two structures were
built for each flavonoid that has an asymmetric B ring, where a 180° rotation of the B
ring was used to generate the second structure. In these cases, both structures were
docked to the PIM-1 model.
In all calculations we started with the inhibitor in the ATP binding site,
specifically the pocket occupied by the adenine ring. Initially, a Monte Carlo docking
was performed using quercetin to identify possible locations, orientations, and ligand
conformations (poses) within the ATP binding site. The structures were refined using
simulated annealing molecular dynamics from a simulated temperature of 500 to 300
Kelvin for 5000 fs and energy minimized using 500 steps of conjugate gradient
minimization or until a maximum derivative of less than 0.01 (kcal/mol/A) was reached.
The results produced ten flavonoid poses that allow sampling of all the reasonable
available conformational space within the ATP binding site. These ten poses were then
used as the initial pose for docking all inhibitors using the above simulated annealing
protocol except that 1000 steps of conjugate gradient minimization was used instead of
500.
All simulated annealing calculations used the CFF forcefield with unit scaling
factors for all energy terms. For the electrostatic term, we used a distance dependent
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dielectric with a value of 1.0. During the docking and minimization calculations the side
chains of amino acid residues within 4 A of the ATP binding site (Leu-44, Val-52, Ala65, Lys-67, lie-104, Arg-105, Leu-120, Glu-121, Asp-167, Lys-169, Glu-171, Asn-172,
Leu-174, He-185, Asp-186) were allowed to move without restraint. Atoms in the hinge
region (Arg-122 to Asp-128) and in a neighboring loop (He-175 to Lys-183) were
allowed to move without restraint, with the exception of the hinge alpha carbon atoms.
whose coordinates were tethered using a harmonic potential with a force constant of 30
kcal/mol- A2. The coordinates of all other PIM-1 atoms were held constant. During all
docking and minimization calculations the center of mass of each flavonoid was
restrained to within 5 A of its starting position to prevent inhibitors from leaving the
active site during docking and increase the number of successful docking calculations;
otherwise all flavonoid atoms were unrestrained.
The interaction energy (IE) represents the sum of electrostatic and Van der Waal’s
terms calculated between atoms in the PIM-1 kinase and atoms in the docked ligand
using the CFF forcefield. As such, this number represents a measure of the structural and
electronic complementarity between the ATP binding site of PIM-1 and each flavonoid.
This calculated IE does not take into account differences in the hydrophobic effect
between each inhibitor (due to differences in buried apolar surface area). However, the
set of flavonoid compounds studied is structurally similar and the differences in buried
apolar surface area between inhibitors are small.
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iii. Comparative molecular field analysis (CoMFA)
The complete set of flavonoids for which IC50 values were determined were
randomly divided into a training set and a test set containing 15 and 6 flavonoids,
respectively. The flavonoids in the training set are listed in Table 7 and those in the test
set are listed in Table 8. The training set was used to construct the CoMFA model while
the test set was used to validate the model. The structures for all of the flavonoids were
constructed in SYBYL and energy-minimized by the conjugate gradient method using the
Tripos force field(149).
The flavonoids in both the training and the test sets all have a common double
six-membered ring structure; hence atoms in that ring structure were used to create the
alignment rule. All of the structures in the training set were aligned over the atoms C4,
C5, C6, C7, and C8. Similarly, the flavonoids in the test set were also aligned over the
atoms C4, C5, C6, C7, and C8. CoMFA, using default parameters, was calculated in the
QSAR option of SYBYL 6.5. The CoMFA grid spacing was 2.0 A in the x, y, and z
directions, and the grid region was automatically generated by the CoMFA routine to
encompass all molecules with an extension of 4.0 A in each direction. An sp3 carbon
(sterics) and a charge of+1.0 (electrostatics) were used as probes to generate the
interaction energies at each lattice point. The default value of 30 kcal/mol was used as
the maximum electrostatic and steric energy cutoff.
Using the training set of flavonoids cross-validated and non-cross-validated
partial least squares analyses (PLS) were performed within the SYBYL/QSAR routine.
Cross-validation of the dependent column (-log IC50) and the CoMFA column was
performed with 2.0 kcal/mol column filtering. Scaled by the CoMFA standard deviation,
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the cross-validated analysis generated an optimum number of components equal to 2 and
R2 = 0.495 (Table 5). PLS analysis with non-cross-validation, performed with 2
components, gave a standard error of estimate of 0.376, a probability (R2 = 0) equal to
0.000, and F value (ni = 2, n2 = 12) of 24.792, and a final R2 = 0.805. The relative steric
(0.626) and electrostatic (0.374) contributions to the final model were contoured as the
standard deviation multiplied by the coefficient at 80% for favored steric (contoured in
green) and favored positive electrostatic (contoured in blue) effects and at 20% for
disfavored steric (contoured in yellow) and favored negative electrostatic (contoured in
red) effects.
To compare the CoMFA contours with the PIM-1 crystal structure, the PIM-1
kinase crystal structure with bound quercetagetin was superimposed onto the
quercetagetin structure in the training set of compounds used to create the CoMFA model
over atoms 01, C2, C3, C4, C5, C6, C7, and C8.

C. Analysis
i. Homology Modeling
The Verify function of Profiles 3D within Insightll was used to assess the
correctness of the model. Additionally, the Prostat structure check function was used to
determine the percentage of phi and psi angles in the model that populate the core region
of the Ramachandran plot.
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ii. Docking
The utility of our docking experiments were assessed by performing a correlation
analysis between IE and experimental IC50 value for the set of docked flavonoids.

iii. Comparative molecular field analysis (CoMFA)
To determine the utility of the CoMFA model, the model was used to predict the
IC50 values of the test set of flavonoids. A correlation analysis was then performed
between the predicted values and the experimental IC50 values. Lastly, we superimposed
the PIM-1 kinase crystal structure onto the model to determine if the properties of the
amino acid residues involved in flavonoid binding are congruent with those indentified in
the CoMFA model.

2.2.3. Small Molecule Library Screening
A. Reagents
i. Recombinant GST-PIM-1 and GST-BAD
Recombinant GST-PIM-1 and GST-BAD was produced and purified as described
above (see section 2.1.1 .A).

ii. Biotin-BAD peptide
The biotin-BAD peptide was synthesized as describe above (see section
2.1.3.A.ii.)
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iii. Small molecule inhibitor library
The small molecule inhibitor library consisting of 1,200 compounds was
purchased from TimTec, Inc (Newark, DE). Additional flavonoid compounds were
purchased from the Indofine Chemical Co., Inc. (Hillsborough, NJ).

iv. GST-PIM-2
The protocol to produce and purify recombinant GST-PIM-2 was performed
similarly to the method described above for recombinant GST-PIM-1 (see section
2.1.1.A). The cDNA for human PIM-2, in the bacterial expression plasmid pGEX2T,
was used to transform BL21 E. coli cells (Novagen).

v. Ribosomal S6 kinase 2 (RSK2) and cAMP-dependent protein kinase (PKA)
RSK2 and PKA were purchased from Cell Signaling (Beverly, MA).

B. Technique
i. Small molecule library screening
The library of 1,200 compounds having structural affinities to known kinase
inhibitors (TimTec, Inc.) was screened once with our ELISA-based kinase assay (solid
phase) as described above (see section 2.1.2.B). Each compound was screened at about a
10 pM concentration. Positive hits were re-screened at the same concentration.
Compounds that had reproducible activity at 10 pM were then screened as described
above (section 2.I.2.B.) to determine their IC50 values. The IC50 value is the
concentration of compound that results in a 50% decrease in the initial velocity of the
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PIM-1 kinase phosphorylation reaction. The additional flavonoid compounds purchased
from the Indofine Chemical Co., Inc. (Hillsborough, NJ) were also screened to determine
their IC50 values.

ii. Lineweaver-Burk analyses
We performed Lineweaver-Burk analyses to determine to mode of quercetagetin
inhibition of the PIM-1 kinase. ELISA-based kinase assays (liquid phase) were
performed similarly to the method described above (section 2.1.3.B). Five concentrations
of ATP and three concentrations of quercetagetin were used while the concentrations of
the PIM-1 kinase, biotin-B AD peptide, and all other reaction components were kept
constant.

iii. Comparative kinase inhibition assays
Kinase assays to determine the relative potency of quercetagetin on the PIM-1
kinase, PIM-2 kinase, PKA and RSK2 were performed using the ELISA-based kinase
assay (liquid-phase) as described above (see section 2.1.3.B). The amounts of kinase and
substrate used were adjusted for each kinase to ensure a linear reaction velocity for the
duration of each reaction. PKA (0.25 ng/reaction; Cell Signaling) was used with 60
ng/reaction biotin-B AD peptide; GST-PIM-2 (25 ng/reaction; produced in our laboratory)
was used with 30 ng/reaction biotin-B AD peptide; and RSK2 (12 ng/reaction; Cell
Signaling) was used with 100 ng/reaction biotin-B AD peptide.
Experiments to assess the potency of quercetagetin against a panel of additional
kinases (JNKlal, PKA, Aurora-A, c-RAF, and PKC0) were conducted using Upstate
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Cell Signaling Solutions’ KinaseProfiler™ service
(http://www.upstate.com/features/kp.asp), according to the protocols detailed at
http://www.upstate.com/features/kp protocols.asp.

C. Analysis
i. Small molecule library screening
Sigmoidal dose response nonlinear regression analyses using a single binding site
model were performed using GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com.

ii. Lineweaver-Burk analyses
Lineweaver-Burk and linear regression analyses were performed using GraphPad
Prism version 4.00 for Windows, GraphPad Software, San Diego California USA,
www.graphpad.com.

iii. Comparative kinase inhibition assays
To determine IC50 values, sigmoidal dose response nonlinear regression analyses
using a single binding site model were performed using GraphPad Prism version 4.00 for
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. Upstate
Cell Signaling Solutions’ KinaseProfiler™ service
(http://www.upstate.com7features/kp.asp) was used according to the protocols detailed at
http://www.upstate.com/features/1cp protocols.asp.
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2.3. Determine the Effect of the Lead PIM-1 Kinase Inhibitor Compound on
Mammalian Cells (Specific Aim 3)

We performed numerous in vitro assays to identify a small molecule inhibitor of
the PIM-1 kinase. The screening of the small molecule library, comparative kinase
inhibition assays, and Lineweaver-Burk analyses have already been described above (see
the Methods subsection entitled ELISA-based Kinase Assay). All of these assays
involved the use of recombinant PIM-1 kinase outside of a cellular environment. We
performed additional experiments to determine the effect of the flavonoid quercetagetin
on the PIM-1 kinase within a cellular environment.

A. Reagents
i. Creation of PIM-1 expressing stable clones
We used retroviral infection to develop RWPE-2 cells, (an established human
tumorigenic prostate cell line), that stably express the PIM-1 kinase. The coding region
for the human pim-1 gene was cloned into the Hindlll and Hpal sites of the pLNCX
retroviral vector (Clontech) under control of the CMV promoter. To produce infectious
viruses the pantropic GP-293 packaging cell line was co-transfected with retroviral vector
pLNCX or pLNCX//?mi-/ and pVSV-G, a plasmid that expresses the envelope
glycoprotein from vesicular stomatitis virus, using a calcium phosphate transfection kit
(Promega). After 48 hours of incubation the media was collected and virus particles were
concentrated as described in the manufacturer’s protocol (Clontech). Human tumorigenic
prostate cells (RWPE-2) were plated at 1 x 105 per 60-mm plate 16-18 hours before
infection. Cells were infected with 5 x 104 viral particles in the presence of 8 pg/ml of
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polybrene. After 6 hours of incubation the virus-containing media was replaced with
fresh media and the next day 400 pg/ml of G418 was added to select stably infected cell
populations. After 10 days of selection stable cell pools were established.

B. Technique
i. Cellular assays to determine the effect of quercetagetin on PIM-1 kinase activity in
PIM-1 expressing mammalian cells
Cells were maintained and seeded in Keratinocyte medium supplemented with
epidermal growth factor and bovine pituitary extract (Gibco). RWPE-2 cells stably
infected with the retroviral vector pLNCX (Clontech) or pirn-1 encoding retroviral vector
(pLNCXZpim-1) were seeded in 6 well plates at 5 x 104 cells/well. After an overnight
incubation in 5% CO2 at 37°C the complete medium was removed and replaced with
supplement-free Keratinocyte medium. Cells were then incubated for an additional 20
hours in the absence of supplements. Quercetagetin, or an equivalent volume of DMSO,
was added to the cells 2 hours or 30 minutes prior to the end of the starvation period. At
the conclusion of the starvation period the cells were washed twice with PBS and
subsequently lysed with SDS lysis buffer (1% SDS, lOmM Tris, 5mM EDTA, 50mM
NaCl, protease inhibitor cocktail set V (Calbiochem), and 10 mM PMSF). The lysates
were normalized by total protein content which was determined using a BCA™ protein
assay (Pierce). Next, the lysates were electrophoresed and immunoblotted with antiphospho-BAD serine 112 (Cell Signaling) or anti-BAD antibody (Transduction Labs),
and anti-PIM-1 antibody (Santa Cruz). A goat anti-mouse HRP conjugated secondary
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antibody (Pierce) was used in each case. The membranes were stripped between primary
antibody incubations with Restore™ Western Blot Stripping Buffer (Pierce).

ii. Assays to determine the effect of quercetagetin on the morphology of RWPE-2 cells
To determine if quercetagetin causes a change in cell morphology, uninfected
RWPE-2 cells were cultured overnight in keratinocyte medium, complete with
supplements, in the presence of 25 pM quercetagetin or an equivalent volume of DMSO.

iii. Assays to determine the effect of quercetagetin on the survival of RWPE-2 cells
To determine the effect of quercetagetin on cell survival, uninfected RWPE-2
cells were cultured overnight in keratinocyte medium in the absence of supplements. The
next day, 25 pM quercetagetin, 10% FBS, 10 nM PMA, or DMSO were added to the
cells. At the end of a 5-day culture period the amount of live cells present was
determined by crystal violet staining. Cells were washed 2X with PBS and fixed with 4%
paraformaldehyde for 2 hours at room temperature. Then the cells were washed again
and stained with a 1:4 crystal violet solution (in water) for 1 hour at room temperature.
The cells were then washed 4 times with water to remove all of the extracellular stain.
Then the intracellular stain was extracted from the cells using a 10% acetic acid solution
(in water). Lastly, the intensity of the color was measured using an ELISA plate reader at
570 nm.
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C. Analysis
i. Creation of PIM-1 expressing stable clones
Pim-1 expression in stable clones was verified by Immunoblot analysis.

ii. Cellular assays to determine the effect of quercetagetin on PIM-1 kinase activity in
PIM-1 expressing mammalian cells
PIM-1 kinase activity was assessed by Immunoblot analysis for the presence of
phospho-BAD and normalized to the amount of total BAD present.

iii. Assays to determine the effect of quercetagetin on the morphology of RWPE-2 cells
The morphology of RWPE-2 cells after incubation with quercetagetin was
examined under a microscope using Hoffmann modulation.

iv. Assays to determine the effect of quercetagetin on the survival of RWPE-2 cells
The amount of live cells present after incubation with quercetagetin was
determined by crystal violet staining.

56

CHAPTER 3
RESULTS
3.1. Development of an Efficient Kinase Assay for the Evaluation of Potential PIM1 Kinase Inhibitors (Specific Aim 1)
3.1.1. Immunoblot-based Assay
Initially, we used the Immunoblot assay to evaluate the potency of potential PIM1 kinase inhibitors. The assay was demonstrated to be an effective method of
determining if potential PIM-1 kinase antagonists possessed inhibitory activity against
the PIM-1 kinase. Results of a typical assay are pictured below in Figure 13.

Figure 13. Typical results of the Immunoblot-based kinase assay. The radiograph
demonstrates decreased amounts of phosphorylated product in the presence of increasing
concentrations of a PIM-1 kinase inhibitor. Neg Ctrl = no PIM-1 kinase; pos ctrll = no
inhibitor, no DMSO; pos ctrl2 = no inhibitor, added DMSO; 33- 166 pM =
concentration of PIM-1 kinase inhibitor.
While the Immunoblot-assay could successfully identify PIM-1 kinase inhibitors,
it also had some limitations. Because the kinase assay was performed in microcentrifuge
tubes, the number of simultaneous reactions that could be conducted were limited by the
amount of microcentrifuge tubes the researcher could effectively handle (in the case of
this researcher, about 10 tubes). Additionally, analysis by immunoblotting was limited
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by the number of lanes in the polyacrylamide gel used for the SDS-PAGE. Furthermore,
densitometry was required to quantify the radiographic results, adding an additional step
to the protocol. Lastly, IC50 values for PIM-1 kinase inhibitor compounds had to be
estimated based on the intensity of the bands on the radiograph. The IC50 values obtained
in this manner lacked sufficient accuracy for the purposes of this project. To address
these limitations we designed an ELISA-based kinase assay.

3.1.2. ELISA-based Assay (Solid phase)
Figure 14 demonstrates that the ELISA-based kinase assay successfully identified
PIM-1 kinase inhibitors, with easy distinction between the relative potencies of each
potential inhibitor.

100-

£
£
< *.
I

[Flavonoid] (|iM)

Figure 14. Typical results of the ELISA-based kinase assay. Illustrated are
three typical inhibition curves obtained from the ELISA-based assay. PIM-1 kinase
activity in the absence of inhibitor is referenced as 100% activity.
The ELISA-based kinase assay proved to be a more robust and effective screening
protocol than the Immunoblot-based assay. The advantages of the ELISA-based kinase
assay over the Immunoblot-based protocol are summarized below in Table 1. In short the
ELISA-based kinase assay allows for the simultaneous analysis of many more samples in
a substantially shorter period of time than the Immunoblot-based method. Additionally,
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the results obtained from the ELISA-based method are numerical in nature and require no
further manipulation for quantification.

Table 1. The advantages of the ELISA-based kinase assay over the Western-blot
based protocol.
Western Blot-based Assay
ELISA-based Assay
1. The number of simultaneous reactions is 1. The number of simultaneous reactions is
limited by the number of wells on the
limited by the number of
plate (96 wells).
microcentrifuge tubes that the
researcher is able to control all at the
same time (approximately 10).
2. The number of samples analyzed
2. The number of samples analyzed
simultaneously is limited by the number
simultaneously is limited by the
number of wells in the polyacrylamide
of wells on the plate (96 wells).
gel (approximately 10).
3. Requires 4 hours to complete.
3. Requires 2 days to complete.
4. The results are bands on a radiograph
that must be quantified by
densitometry.

4. The results are numerical absorbance
units that require no further
manipulation to quantify.

3.1.3. ELISA-based Assay (Liquid Phase)
The liquid phase ELISA-based assay represents an improvement over the solid
phase ELISA-based assay. The liquid phase version of the ELISA-based assay allowed
for the use of a biotin-BAD peptide substrate rather than recombinant GST-BAD. As a
result the kinase reaction could be performed with both the kinase and substrate in the
liquid phase of the reaction, rather than having the substrate immobilized to the bottom of
the plate. Under these conditions we were able to better reproduce the reaction kinetics
that occur within a cellular environment. Additionally, the peptide substrate was more
convenient to prepare and purify for use in multiple experiments than recombinant GSTBAD, which led to increased reproducibility of results.
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3.2. Identification of a Lead Compound for a PIM-1 Kinase Inhibitor (Specific Aim
2)
3.2.1. Phage Display
Phage display was performed to identify random peptide sequences that will bind
to the PIM-1 kinase. Using the PhD-12 Phage Display Peptide Library Kit three rounds
of biopanning were performed. After the 3rd round of biopanning a proof of enrichment
experiment was conducted to determine if the three rounds of biopanning had
successfully enriched the population of phage for phage expressing PIM-1 binding
peptides. One round of biopanning was performed using similar titers of the original
PhD-12 (1.5 x 106) and the BP3 phage (1.6 x 106). At the completion of one round of
biopanning the quantity of PIM-1 binding phage was determined. The BP3 phage
contained 3.7 x 103 pfu/mL while the original PhD-12 library contained only 4 x 101
pfii/mL (Table 2). Hence the BP3 phage had 92.5 times more PIM-1 kinase binding
phage than the original PhD-12 phage library. These data demonstrate that we
successfully enriched the original PhD-12 phage library for PIM-1 binding phage.

Table 2. Proof of Enrichment of the Ph.D.-12 Random Peptide Library for PIM-1
Kinase Binding Phage.
Input Phage (total) Output Phage (total) Percent Recovered
1.5 x 106
0.00267
4 x 101
PhD-12
3.7 x 103
1.6 x 106
0.231
BP3

The proof of enrichment experiment for the BP3 phage essentially represents a
fourth round of biopanning, hence the PIM-1 binding phage resulting from this
experiment have been designated BP4 phage. Ten plaques were randomly chosen from
the titer plate for the BP4 phage and the representative phage DNA was sequenced. The
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random 12 amino acid residue peptide sequence displayed by each phage was then
determined from the DNA sequence of each individual phage. Five of the ten phage
sequenced displayed the same peptide - HGVKKJRJPHNPYG (HGV). Each of the
remaining five phage displayed a different and unique peptide sequence (Table 3).

Table 3. The Peptide Sequences Displayed by PIM-1 Kinase Binding Phage.
Peptide Sequence
Plaque
RNSNGAVLFRPV
1
HGVKKRPHNPYG
2, 3, 4, 7, 8
IPFIATDPGFPR
5
DTPFNTQLLSPR
6
DVANLSTTHTEL
9
NYHNTPAQFLST
10

When comparing the six different displayed peptides there do not appear to be
any obvious similarities among them. The fact that 50% of the phage sequenced
displayed the same peptide, HGV, suggests that this peptide binds more successfully to
PIM-1 than the other peptides represented. Further examination of this peptide reveals
that it has significant sequence similarity to the PIM-1 phosphorylation sites of the
tyrosine phosphatase PTP-U2S and the pro-apoptotic protein BAD, both of which are
known PIM-1 substrates. HGV is also similar in sequence to pimtide, a 14 amino acid
residue peptide that represents a consensus sequence of known PIM-1 substrates and is
itself also phosphorylated by PIM-1. Aligning the PIM-1 substrate sequences by the
phosphorylated residues reveals some common features. In each case there are a string of
positively charged amino acid residues upstream of the phosphorylated residue.
Additionally, a proline residue invariably follows the phosphorylated residue in the +2
position. The sequence of HGV is strikingly similar to the sequences of the PIM-1
substrates, and contains these same features (Figure 15). HGV does not contain any
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serine or threonine residues; hence it cannot be phosphorylated by the PIM-1 kinase.
However, aligning HGV and the PIM-1 substrate sequences with the histidine residue in
the position of the phosphorylated residues reveals the sequence similarity between HGV
and the PIM-1 substrates. HGV contains a string of positively charged amino acids
upstream of the phosphorylation position, with a proline in the +2 position. The ability of
HGV to bind to PIM-1 and HGV’s sequence similarity to known PIM-1 kinase
phosphorylation sites suggests that it is a pseudo-substrate of the PIM-1 kinase.

HGVKKRPHNPYG -phage
NGLKKRKLTNPV
—ptpu2s
VEIRSRHSSYPAGT -bad
ARKRRRHPSGPPTA -pimtide

Figure 15. Sequence alignment of the PIM-1 binding peptide, HGV, with the
sequence of known PIM-1 substrates. In each case the residue phosphorylated by PIM1 kinase is colored red. Upstream positively charged amino acid residues are colored
green and the invariable downstream proline is colored blue.

We conducted in vitro kinase assays to determine if HGV inhibits PIM-1 kinase
activity. While in some of our experiments HGV appeared to inhibit PIM-1
phosphorylation of GST-BAD (Figure 16), these results were inconsistent. Additional
experiments did not consistently demonstrate inhibitory activity of HGV against the PIM1 kinase. While the true inhibitory activity of HGV remains dubious, experiments that
did demonstrate HGV inhibition of PIM-1 activity suggest an IC50 of approximately 50
jjM.
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Figure 16. Inhibition of PIM-1 kinase activity by HGV. Western blot analysis was
performed on samples from a PIM-1 kinase reaction with increasing concentrations of
HGV peptide to determine the amount of phosphorylated product present. Neg Ctrl = no
PIM-1 kinase; pos ctrll = no HGV, no DMSO; pos ctrl2 = no HGV, added DMSO; 33 166 jliM = concentration of added HGV peptide.

We used flow-cytometric analysis and fluorescence microscopy to examine the
ability of HGV to enter cells. FITC-conjugated HGV peptide was complexed with a cell
permeating peptide derived from the HIV-TAT protein by protein-protein association
domains. The FITC-HGV/HIV-TAT complexes were then incubated with U20s cells for
6 hours. After extensive washing intracellular FITC-HGV was detected by flowcytometry and by fluorescence microscopy. Both flow-cytometric analysis (Figure 17A)
and fluorescence microscopy (Figure 17B) reveal that FITC-HGV/HIV-TAT complexes
successfully traverse the cellular membrane and enter the cytoplasm of cells.
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Figure 17. HGV can traverse the cellular membrane and enter cells. A. Flowcytometric analysis of U20s cells incubated with HIV-TAT/ FITC-HGV complexes. 1 =
FITC-HGV (45pg); 2 = FITC-HGV (45|ag) + KVILK-TAT (ISpg); 3 - FITC-HGV
(45pg) + KVILKVILK-TAT (15pg); 4 = FITC-HGV (90pg) + KVILKVILK-TAT
(15pg); 5 = FITC-HGV (135pg) + KVILKVILK-TAT (15pg). B. Fluorescence
microscopy of U20s cells incubated with HIV-TAT/ FITC-HGV complexes. The cell
nuclei are counterstained with DAPI.
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Thus we have demonstrated that HGV is a PIM-l kinase binding peptide having
strong sequence similarity with known PIM-l kinase substrate phosphorylation sites.
Additionally, HGV can enter the cytoplasm of cells and may potentially inhibit PIM-l
kinase activity in low pM concentrations.

3.2.2. Computational Design of a Novel PIM-l Kinase Inhibitor
A. Homology Modeling
A search of the Protein Data Bank using FASTA(147) and the PAM250
matrix(150) for proteins with similar sequence to that of PIM-l (gi: 125565) indicated that
aurora kinase(151), death-associated protein kinase (DAPK)(152;153), phosphorylase
kinase(154), human cell cycle checkpoint kinase(155), and cAMP dependent protein
kinase(156) have the most similar sequence to PIM-l kinase among proteins with
published structures. The number of residues in the catalytic core of the PIM-l kinase,
residues 38-277, that are identical in the above serine/threonine kinase sequences ranged
from 24% to 30%; the percentage of conserved substitutions ranged from 43% to 49%.
Structures that contain a bound ATP or ATP analog are available for all of these
serine/threonine kinases. We limited our choice of template structures to crystal
structures which contain an ATP or ATP analog in the active site with the assumption
that such a structure is the best template for modeling the active site structure when
bound to ATP or competitive inhibitors of ATP binding.
Of these proteins, we chose to use the crystal structure of DAPK (PDB id: 1 IKK)
containing the ATP analog adenosine 5,-(p,y-imino)triphosphte (AMPPNP) and
magnesium as our primary template for modeling the structure of the PIM-l kinase. One
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reason for choosing DAPK as our template was the availability of crystal structures that
are higher resolution and have fewer missing atoms than the aforementioned homologous
serine/threonine kinases. However, our main criterion in selecting a template was
sequence similarity to residues that form the adenosine-binding site in a serine/threonine
kinase. Of the residues with side chain or backbone atoms within 2.5 or 4.0 A of the
AMPPNP in the DAPK crystal structure, 64% and 70%, respectively, of the residues are
identical in the sequence of the PIM-1 kinase; 79% and 87%, respectively, are conserved.
The suitableness of DAPK as a template for modeling the structure of the PIM-1 kinase is
illustrated graphically in Figure 18. The complete alignment of the PIM-1 kinase
sequence with the sequences of the template structures used to build the model is shown
in Figure 19.
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N-terminus
Basic loop

Helix C
Metal-binding loop
Catalytic loop
Activation loop

Helix G

Similarity to PIM-1
■
■
■
□
■
□

C-terminus

Identity
Strongly conserved
Neutral substitution
Non-conserved
Unfavorable substitution
Insertion or deletion

Figure 18. The crystal structure (1JKK) of Death-associated Protein Kinase
(DAPK) with bound AMPPNP ligand (yellow) color coded by sequence similarity to
the PIM-1 kinase. Gray represents deletions of DAPK residues or the residues of DAPK
that flank a point of insertion within PIM-1 kinase sequence. The coloring for the
substitutions was derived from the PAM250 substitution matrix with the following
definitions: 2 = strongly conserved; 0 or 1 = neutral substitution; -1 or -2 = nonconserved; -3 = unfavorable substitution; Red letters indicate helices and
numbers
label p strands. Important loops are labeled in black.
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Figure 19. Sequence alignment of the template structures, Death-associated Protein
Kinase (1JKK) and cAMP-dependent Protein Kinase (1ATP), with the sequence of
PIM-1 used to generate the homology model. Structurally conserved regions (SCRs)
are underlined and numbered. The coordinates of the SCRs were directly assigned to
PIM-1 kinase from the indicated template. {3-strands are numbered and the involved
residues colored cyan, a-helices are lettered and the involved residues colored red. The
hinge region is labeled and colored
. Numbering of the amino acid sequence
applies to PIM-1 kinase. ■ and ■ mark amino acids that contain atoms within 2.5A and
4.0A of AMPPNP, respectively (in the template structure, 1JKK).
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1
Piml MLLSKINSLA HLRAAPCNDL HATKLAPGKE KEPLESQYQV GPLLGSGGFG
1JKK
TVER QENVDDYYDT GEELGSGQFA

PI
51B
Piml SVYSGIRVSD NLPVAIKHVE KDRISDWGEL PNGTRVPMEV VLLKKVSSGF
1JKK VVKKCREKST GLQYAAKFIK KRRTKSSRRG VSREDIEREV SILKEIQ—H
aC
P2
P3
SCR# 1
SCR#2
101
Piml SGVIRLLDWF ERPDSFVLIL ERPEPVQDLF DFITERGALQ EELARSFFWQ
1JKK PNVITLHEVY ENKTDVILIL E
ELF DFLAEKESLT EEEATEFLKQ
P4
p5
aD
aE
SCR#3
SCR #4
151
Piml VLEAVRHCHN CGVLHRDIKD ENILIDLN-- -RGELKLIDF GSGALLK-DT
1JKK ILNGVYYLHS LQIAHFDLKP ENIMLLDRNV PKPRIKIIDF GLAHKIDFGN

P6

p7

p9

P8

SCR #4

SCR#5

197
Piml VYTDFDGTRV YSPPEWIRYH RYHGRSAAVW SLGILLYDMV CGDIPF------1JKK EFKNIFGTPE FVAPEIVNYE -PLGLEADMW SIGVITYILL SGASPFLGDT
pio
aF
SCR#7
Act.Loop SCR#6
243
Piml —EHDEEIIR GQVFFR—
QRVSSECQHL IRWCLALRPS DRPTFEEIQN
1JKK KQETLANVSA VNYEFEDEYF SNTSALAKDF IRRLLVKDPK KRMTIQDSLQ
1ATP PIQIYEKIVS GKVRFP-SHFSSDLKDL LRNLLQVDLT KRFGNLKLGV
aH
aG
ai
SCR# 9
SCR#8
287
Piml HPWMQDVLLP QETAEIHLHS LSPGPSK
1JKK HPWIKP
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After preparing the sequence alignment we observed that the hinge region of the
PIM-1 kinase (residues 122 - 128) is unique in both sequence and length. The hinge
region of the PIM-1 kinase contains an insertion compared to typical kinases, having
seven amino acid residues as opposed to the standard six-residue hinge. Additionally, the
sequence of the PIM-1 kinase hinge region contains two proline residues, an extremely
uncommon feature. Furthermore we observed that the presence of a proline at residue
123 would preclude the ability of the PIM-1 kinase to form a canonical hydrogen bond to
the adenosine moiety of ATP. An extensive search of known kinase sequences failed to
identify any kinases with sequence similarity to the PIM-1 kinase in the hinge region,
save the PIM-2 and PIM-3 kinases. These data suggest that the PIM family of kinases
share a structurally unique hinge region, a feature that may be exploited in the design and
development of a selective PIM-1 kinase inhibitor. The sequences of the hinge regions of
the PIM family of kinases, in addition to other common kinases, are shown in Figure 20.

PIM1
PIM2
PIM3
DAPK
PKA
PHK

SFVLILE
GFMLVLE
GFLLVLE
DVILILE
NLYMVME
FFFLVFD

RPEPVQD
RPLPAQD
RPEPAQD
LVAGG-E
YVAGG-E
LMKKG-E

LFDFITER
LFDYITEK
LFDFITER
LFDFLAEK
MFSHLRRI
LFDYLTEK

Figure 20. Sequence alignment of the hinge regions of the PIM family of kinases.
The hinge (middle column) and flanking regions of the PIM family of kinases are aligned
with Death-associated protein kinase (DAPK), cAMP-dependent protein kinase (PKA)
and Phosphorylase kinase (PHK). Note the insertion of a glutamine residue (Q) in the
hinge region of each of the PIM kinases. Also note the proline residues (P) present only
in the hinge regions of the PIM kinases.
We assessed the correctness of our PIM-1 kinase homology model using the
Verify function of Profiles-3D within Insightll. Verify measures the compatibility of a
hypothetical structure with its own sequence. The self-compatibility score expected for a
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protein the size of the PIM-1 kinase is 115.0. Our PIM-1 kinase homology model
received score of 115.2.
We also determined the percentage of phi and psi angles in our model that
populate the core region of the Ramachandran plot. Using the Prostat structure check
function of Insightll we determined that 79.7 percent of the phi and psi angles in our
PIM-1 kinase homology model lie within the core region of the Ramachandran plot.
These data strongly suggest that our model is a valid protein structure.
Several months after the completion of our PIM-1 kinase model, two crystal
structures of the PIM-1 kinase were published by independent groups, first by Qian et
al(157), then a little later by Kumar et al(158). The availability of a PIM-1 kinase crystal
structure allowed us the unique opportunity to evaluate the accuracy of our model. We
compared the root mean square deviation (RMSD) between our model and the first
published crystal structure of the PIM-1 kinase (PDB id 1XQZ; see Table 4). Our model
was structurally similar to the published crystal structure, especially in secondary
structure elements (ct-helices and p-sheets), with the areas of dissimilarity being mostly
confined to non-conserved loop regions. The RMSD over the entire molecule was 3.14 A
while the RMSD of just the ATP-binding site was only 1.46 A. This comparison
demonstrates that our model was structurally similar to that of the crystal structure,
especially within the region involved in ATP-binding. The similarity between our model
and the PIM-1 kinase crystal structure is illustrated graphically in Figure 21.
Additionally, the crystal structures reported by both groups confirmed our observations
concerning the unique nature of the hinge region of the PIM-1 kinase.
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Table 4. Similarity between the PIM-1 kinase model and the PIM-1 kinase crystal
structure (PDB id 1XQZ)
RMSD (A)
Region
Residues
4.65
72-88
Loop preceding a-helix C
2.15
122-128
Hinge
194-201
2.20
Activation Loop
44, 49, 50, 52, 65, 67, 73, 104,
ATP-binding
1.46
120, 121, 122, 172, 174, 185,
186
38-70,
89-97,
104-121, 128SCRs Only
1.33
176, 180-193,202-213,220242
3.14
Complete Catalytic Core
38 - 290

Figure 21. Similarity of the PIM-1 kinase homology model to a published PIM-1
kinase crystal structure. The structures were superimposed over the backbone atoms of
residues 28 - 290. The model is displayed in dark blue and the crystal structure, 1XQZ, is
displayed in light blue.

72

These data demonstrate the development and validation of a three-dimensional
model of the PIM-1 kinase. In the absence of a crystal structure of the PIM-1 kinase, our
model served as a useful tool in elucidating the structurally unique features of the PIM-1
kinase.

B. Docking
We docked a test set of 10 flavonoids to our PIM-1 model and evaluated the
computational measure of binding, interaction energy (IE), for each flavonoid in the test
set. Then we compared the IE for each flavonoid in the test set with the experimentally
determined IC50 values to determine if the computational measure of binding correlates
with experimental potency. For the test set the two most potent inhibitors, quercetagetin
and S^S^d’jS’-pentahydroxyflavone, also had the lowest IBs. However, based on their
potencies, some of the flavonoids had much lower IBs than expected (for example,
T^^d^S’-tetrahydroxyflavone), while others (such as 3,7,4’-trihydroxyflavone) had
much higher IBs than anticipated (Table 5). For the complete test set, the IE did not
correlate strongly with IC50 (R2 = 0.44), which suggests that the docking/scoring method
employed did not accurately predict the potency of flavonoid inhibitors of the PIM-1
kinase.
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Table 5. Docking of the Test Set of Flavonoids to the PIM-1 Kinase Model
Docking Score
Flavonoid
Measured IC50 (|aM)
107
-38.54
(S) 5,7-dihydroxyflavanone
4.6
-40.24
3,7-dihydroxyflavone
15
5,7 -dihydroxy flavone
-41.16
-46.44
4.5
7,3’-dihydroxyflavone
0.94
-47.94
apigenin
22
-48.76
7,8,4’-trihydroxyflavone
0.98
-53.26
3,7,4’ -trihydroxy flavone
7.8
-65.38
7,3 ’4’ 5 ’ -tetrahydroxyflavone
-69.24
0.65
S^SM’S’-pentahydroxyflavone
0.34
-70.48
quercetagetin
R2 = 0.44

C. Comparative Molecular Field Analysis (CoMFA)
Using the QSAR option of SYBYL (Tripos) we generated a CoMFA model of the
PIM-1 kinase ATP-binding site using flavonoid inhibitors as probes. The 21 flavonoids
for which experimental IC50 values were determined were randomly divided into a
training set and a test set, having 15 and 6 flavonoids in each set, respectively. The
training set was used to create the CoMFA model, while the test set was used to validate
the model. A cross-validated partial-least-squares regression analysis using -log IC50 and
CoMFA score was performed. The analysis generated an optimum number of
components equal to 2 and a correlation coefficient of R2 = 0.495 (Table 6).

Table 6. Cross-Validated PLS Analysis
W
Components
s
0.303
1
0.682
0.487
0.610
2
0.416
0.679
3
0.450
4
0.691
0.374
0.778
5
0.318
0.861
6
s, standard error for the estimate of -log IC50; R2, correlation coefficient. Optimum
number of components is 2 with R = 0.487.
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A traditional non-cross-validated analysis of predicted -logICso and actual logICso using 2 components generated a correlation coefficient of R2 = 0.805 for the
training set (Table 7) with a 0.000 probability that R2 = 0. We validated the model by
determining how well it can predict the IC50 values of the test set of flavonoids. To do so
we compared the predicted -logICso with the experimental -logICso for each flavonoid in
the test set. The model showed a strong correlation between predicted -logICso and
experimental -logICso with a correlation coefficient of R2 = 0.826 (Table 8). These data
verify that the CoMFA model can successfully predict the potency of flavonoid inhibitors
of the PIM-1 kinase.

Table 7. PIM-1 Inhibition Activities for the Training Set Used in the Non-CrossValidated Analysis
-Log IC50 (pM)
Observed Predicted
Residual
Compound
-0.73
-1.78
-1.05
(R)-5,7-dihydroxy flavanone
0.67
-1.1
-1.76
(S)-5,7-dihydroxy-8-(3-methylbut-2-ene)flavanone
-0.46
-1.34
-0.89
7,8,4’ -trihydroxy flavone
-0.78
0.35
-0.43
Morin
0.33
-0.66
-0.98
7,3 ’-dihydroxy flavone
0.2
0.27
0.47
Quercetagetin
-0.25
-2.03
-1.78
(S)-5,7,-dihydroxyflavanone
0.21
-0.04
-0.25
Quercetin
-0.18
0.11
0.28
Myricetin
-0.17
-0.98
-1.15
7-hydroxy flavone
0.21
0.16
0.37
Gossypetin
-0.12
-0.08
-0.2
Luteolin
0.09
-0.06
0.03
Apigenin
0.19
0.23
-0.05
5,7,3’ ,4’ ,5 ’-pentahydroxyflavone
-0.03
-0.89
-0.86
7,3 ’ ,4’,5 ’-tetrahydroxyflavone
Number of components = 2, s = 0.376, R2 = 0.805.
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Table 8. Predicted and Observed PIM-1 Inhibition Activities for the Test Set
-Log IC50 (iiM)
Observed
Predicted
Residual
Compound
0.04
-0.92
-0.77
3,6,2 ’ ,4 ’ -tetrahy droxy flavone
0.00
0.01
0.10
3,7,4'-trihy droxy flavone
0.02
-0.66
-0.89
3.7-dihydroxyflavone
-0.94
0.00
-1.18
5.7-dihydroxy flavone
0.07
0.20
0.01
fisetin
-0.41
-0.41
-0.11
kaempferol
R"= 0.826

The steric and electrostatic contributions to the model were determined to be
0.626 and 0.374, respectively, and are represented graphically in Figure 22. For
electrostatic contributions the model predicts that increased binding will result by putting
more negative charges near the C4’ position and more positive charges near C8. For
steric contributions the model predicts that adding bulk near the C3’ and C6’positions
will improve binding.
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Figure 22. Electrostatic and steric CoMFA fields for the training set of flavonoids.
For the electrostatic contours increased binding is predicted by placing more positive (+)
charges near blue areas and more negative (-) charges near red areas. The steric contours
predict increased binding by placing more bulk near green areas and less bulk near
yellow areas. Quercetagetin is pictured amid the electrostatic and steric contours.
We examined the interactions of the most potent PIM-1 antagonist, quercetagetin
(IC5o = 0.34 pM), and the least potent flavonoid, (S)-5,7-dihydroxyflavanone (IC50 =107
pM), with the steric and electrostatic contours of the model. The model elucidates at
least one reason for the dramatic differences in potency between these to flavonoid
compounds. As illustrated in Figure 23, quercetagetin lies almost completely flat within
the contours. In this position the C3’ and C4’ hydroxyl groups on the B ring are directed
toward the area that the model reveals as favorable for negative charges. In contrast, (S)5,7-dihydroxyflavanone has a chiral center at the C2 position and does not lie flat within
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the counters. The B ring of this flavonoid is positioned deep within a region where the
model predicted less bulk would improve binding. Hence the model elucidates why (S)5,7-dihydroxyflavanone is a poor PIM-1 kinase inhibitor, i.e. the position of the B ring
produces steric hindrances that discourage flavonoid binding.

Figure 23. Comparison of the best and poorest flavonoid inhibitors of the PIM-1
kinase within the contours of the CoMFA model. Quercetagetin, the most potent
inhibitor, is pictured in gray. (S)-5,7-dihydroxyflavanone, the poorest inhibitor, is
pictured in purple. For the electrostatic contours increased binding is predicted by
placing more positive (+) charges near blue areas and more negative (-) charges near red
areas. The steric contours predict increased binding by placing more bulk near green
areas and less bulk near yellow areas.
We sought to further validate the CoMFA model by comparing the steric and
electrostatic contours of the model with a PIM-1 crystal structure. We have available to
us an as yet unpublished crystal structure of the PIM-1 kinase with bound quercetagetin
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(a gift from Plexxikon, Inc.). We superimposed the quercetagetin in the crystal structure
onto the quercetagetin in the CoMFA fields and examined amino acid residues involved
in flavonoid binding. In the areas where the model predicts improved binding by the
addition of more positive charges, there are potential interactions with negatively charged
acidic side chains (Glu 121 , Asp

126

, Asp131, Glu171). Similarly, the electrostatic contour

identifying areas where addition of negative charges will improve binding envelops the
positively charged side chain of Lys

(Figure 24A). The steric fields were also confirmed

by the PIM-1 kinase crystal structure. The bulky side chains of Val52, Ala65, and Leu 120
sterically hinder large groups in the areas identified by the model where reduced bulk will
improve binding. The model even identified a solvent exposed area near C7 as a region
where reduced bulk would improve binding. The side chain of Phe49 and those of He 104
and He185 form two hydrophobic pockets. The model accurately identified both of these
pockets as regions were the addition of bulk would improve binding (Figure 24B).
Hence, a comparison of the electrostatic and steric CoMFA fields with the PIM-1 kinase
crystal structure validates the striking accuracy of our CoMFA model of the PIM-1
kinase.
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Figure 24. Validation of the electrostatic and steric CoMFA fields with a
superimposed PIM-1 kinase crystal structure. The crystal structure of the PIM-1
kinase in complex with quercetagetin is superimposed on the CoMFA fields using the
positions of quercetagetin in the crystal and in the model. For clarity, only the amino
acid residues contributing to the properties of a CoMFA contour are shown. The pictured
flavonoid is the CoMFA model quercetagetin structure; to reduce visual clutter the PIM-1
crystal quercetagetin structure is not shown. A . For the electrostatic contours increased
binding is predicted by placing more positive (+) charges near blue areas and more
negative (-) charges near red areas. B. The steric contours predict increased binding by
placing more bulk near green areas and less bulk near yellow areas.
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The steric restrictions of the PIM-1 ATP binding site are further elucidated by the
relationship between volume and potency for flavonoid inhibitors of the PIM-1 kinase.
Figure 25 demonstrates that there appears to be an optimum volume of about 218 A3 (the
volume of quercetagetin) for flavonoid antagonists of PIM-1. Flavonoids with larger or
smaller volumes are progressively worse inhibitors of the PIM-1 kinase.
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Figure 25. The volume of a flavonoid is related to its potency as an inhibitor of the
PIM-1 kinase. The labels on the points represent the volume of each inhibitor. The
inhibitors represented, from lowest volume to highest volume, are 7-hydroxyflavone,
7,8,4’-trihydroxyflavone, (S)-5,7-dihydroxyflavone, (R)-5,7-dihydroxyflavone,
7,3,,4,,5,-tetrahydroxyflavone, quercetin, quercetagetin, and (S)-5,7-dihydroxy-8-(3methylbut-2-ene)flavanone.

Based on the PIM-1 kinase CoMFA fields, we have designed a small molecule
(SH25) to maximize inhibitor binding to the PIM-1 kinase ATP-binding site (Figure 26).
In designing the small molecule we sought to retain the general shape of a flavonoid,
while moving into a different class of compounds. We chose to use a quinazolone
derivative because quinazolones are very similar in shape to flavonoids, but represent a
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class of compounds that are historically more drug-like (in terms of potency and
selectivity) than flavonoids. To maximize the electrostatic interactions of SH25 we
added an amine group in the C8 position. Further electrostatic modifications resulted in
poorer predicted IC50 values. The steric interactions were maximized by the addition of a
chlorine group in the C6’ position. Further bulky modifications resulted in poorer
predicted IC50 values.
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Figure 26. SH25, a quinazilinol designed to maximize steric and electrostatic
interactions with the PIM-1 kinase ATP-binding pocket. A. The structure of SH25
B. SH25 is pictured in the PIM-1 kinase CoMFA contours. Increased binding is
predicted by placing more positive (+) charges near blue areas, more negative (-) charges
near red areas, more bulk near green areas and less bulk near yellow areas.
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Using the CoMFA model, SH25 has a predicted IC50 of 0-72 pM. By comparison
the most potent flavonoid inhibitor of the PlM-1 kinase that we have identified,
quercetagetin, is predicted by the CoMFA model to have an IC50 of 0.65 uM (actual
experimental IC50 = 0.34 pM). Hence, we designed a small molecule inhibitor of the
PIM-1 kinase, SH25, whose steric and electrostatic properties should render it a selective
inhibitor of the PIM-1 kinase. Additionally, as a quinazolinol, SH25 represents a class of
compounds with improved drug-like properties over flavonoids. Moreover, in designing
SH25 we have retained similar potency to what is observed with quercetagetin.

3.2.3. Screening for a Small Molecule Inhibitor of the PIM-1 Kinase
A. Screening
We used our ELISA-based kinase assay (solid phase) to screen a library of 1,200
small molecules having structural similarity to known kinase inhibitors for activity
against the PIM-1 kinase. We discovered that 6 out of 7 of the most potent small
molecule inhibitors were members of a class of compounds called flavonoids. The only
non-flavonoid inhibitor of the PIM-1 kinase among the 7 most potent small molecule
inhibitors belonged to the anthraquinone family of compounds. Of the 1,200 small
molecules in the complete library, quercetin (3,5,7,3’,4,-pentahydroxyflavone) was
determined to be the most potent small molecule inhibitor of the PIM-1 kinase. The IC50
of quercetin for PIM-1 kinase activity is 1.1 pM.
Having identified the flavonoid class of compounds as possessing inhibitory
activity against the PIM-1 kinase, we screened 15 additional flavonoids in an effort to
identify a more potent PIM-1 antagonist than quercetin. Many of the additional
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flavonoids screened proved to be more potent inhibitors of the PIM-1 kinase than
quercetin. The most potent flavonoid screened was identified as quercetagetin
(3,5,6,7,3\4’-hexahydroxyflavone), whose IC50 was determined to be 0.34 pM. The
structures of all 21 flavonoids screened, in addition to their experimental IC50 values, are
presented below in Figure 27.
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Figure 27. Flavonoids screened for PIM-1 inhibitory activity. The structures of all of
the flavonoids screened for PIM-1 inhibitory activity are illustrated, along with their IC50
values. IC50 values were determined by non-linear curve-fit regression analysis of
inhibition curves using 0.001 pM to 300 pM of each inhibitor.
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B. Characterization of quercetagetin as a selective inhibitor of the PIM-1 kinase
Of all the small molecules screened, quercetagetin is the most potent antagonist of
the PIM-1 kinase. As such, we sought to characterize quercetagetin inhibition of PIM-1.
Previously published reports exist, though not in abundance, showing that flavonoids
bind to the ATP binding pocket of kinases(159; 160). As a result we suspected that
quercetagetin was an ATP competitive inhibitor of the PIM-1 kinase. We investigated
this possibility using Lineweaver-Burk analysis of the kinase reaction kinetics as
described in section 2.2.3.B.ii.
In the presence of increasing concentrations of quercetagetin the Vmax of the
reaction does not change, i.e the y-intercept of the Lineweaver-Burk analysis remains the
same in the absence of quercetagetin or in the presence of increasing concentrations of
quercetagetin. However, the slopes and x-intercepts of the Lineweaver-Burk analysis do
change in the presence of quercetagetin, indicating that quercetagetin affects the Km of
ATP in the reaction (Figure 28). Thus, our results demonstrate that quercetagetin
increases the Km of ATP for PIM-1 without affecting the Vmax of the reaction. These are
the classic characteristics of a competitive inhibitor. Therefore we conclude that
quercetagetin is an ATP competitive inhibitor of the PIM-1 kinase.

88

15n

?c

10-

n
<

5-

o
m

• 2.0 jiM quercetagetin
A 0.5 j^M quercetagetin
• 0 juM quercetagetin

«a m

00.000

0.025

0.050

0.075

0.100

0.125

1/[ATP] (fiM)

Figure 28. Lineweaver-Burk analysis of quercetagetin-meditated inhibition of the
PIM-1 kinase. The data represent a typical experiment performed in triplicate. Point =
mean; error bars = standard deviation.

To assess the selectivity of quercetagetin for the PIM-1 kinase we determined the
IC50 value of quercetagetin towards alternative BAD (serine 112) kinases - Ribosomal S6
Kinase 2 (RSK2), cAMP-dependent Protein Kinase (PKA), and PIM-2 Kinase. The IC50
of quercetagetin for the PIM-1 kinase is 0.34 pM, while for the RSK2, PKA, and PIM-2
kinases quercetagetin has an IC50 of 2.82 pM, 21.2 pM, and 3.45 pM, respectively
(Figure 29A-D). These data demonstrate that quercetagetin is a more potent inhibitor of
the PIM-1 kinase than RSK2, PKA, and even PIM-2 kinase.
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The inhibitory activity of quercetagetin against additional serine/threonine kinases
(JNKlal, PKA, Aurora-A, c-RAF, and PKC9) was examined at two drug concentrations
(Figure 29E), without calculating IC50 values. At a 10 |iM concentration of
quercetagetin, PIM-l kinase and Aurora-A kinase were most affected, their activities
being inhibited by 98% and 93% respectively. In a 1 pM concentration the selectivity of
quercetagetin was demonstrated more dramatically, where PIM-l activity was inhibited
by 92% while the next most susceptible kinase, Aurora-A, was inhibited by 41%. These
data establish that quercetagetin inhibits PIM-l activity more potently than JNKlal,
PKA, Aurora-A, c-RAF, and PKC0 and indicate that quercetagetin is not only a potent
inhibitor of PIM-l kinase, but is also selective for PIM-l, especially at low micromolar
concentrations.

3.3. Determine the Effect of the Lead PIM-l Kinase Inhibitor Compound on
Mammalian Cells (Specific Aim 3)
Having shown that quercetagetin is a potent, selective inhibitor of the PIM-1
kinase in vitro, we considered it to be our lead compound for an inhibitor of the PIM-l
kinase. Consequently, we explored the ability of quercetagetin to inhibit PIM-l activity
within a cellular environment. RWPE-2 cells stably infected with the retroviral vector
pLNCX or pLNCX/p/w-7 were incubated in the presence of quercetagetin or an
equivalent volume of DMSO. The activity of endogenous kinases was reduced by
incubating the cells in the absence of growth factors. Under these conditions PIM-l
specific phosphorylation of BAD was detected by Immunoblot analysis as described in
section 2.3.B.i. The results conclusively demonstrate that PIM-l phosphorylation of
BAD is significantly reduced in the population of cells exposed to quercetagetin
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compared to those exposed to the DMSO control (Figure 30). The inhibition is both time
and concentration dependent. These data confirm that quercetagetin inhibits PIM-1
activity in mammalian cells.

pLNCX

pLNCX/pim-1
2 hrs 30 mins
Quercetagetin
Phospho-BAD
Total-BAD
Pim-1

Figure 30. Quercetagetin inhibits PIM-1 kinase activity in human prostate cells.
RWPE-2 cells stably expressing pim-1 were exposed to quercetagetin for the indicated
time periods. PIM-1 activity was assessed by Western blot analysis for phosphorylated
BAD (serine 112), a substrate of PIM-1 kinase. Western blot analysis for total BAD and
PIM-1 are also shown. D = DMSO. 10 and 25 = 10 pM and 25 pM quercetagetin,
respectively.
Further experiments demonstrated that quercetagetin causes morphological
changes in mammalian tumorigenic prostate RWPE-2 cells. RWPE-2 cells incubated
with 25 pM quercetagetin overnight adopt a flattened appearance, similar to the
morphology of senescent cells (Figure 31 A). In contrast, RWPE-2 cells incubated with
an equivalent volume of DMSO overnight undergo no morphological change, and retain
the fibroblast-like appearance common to this cell line (Figure 3IB). Additionally, 25
pM quercetagetin causes a remarkable reduction in survival of RWPE-2 cells, whereas
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DMSO and 10% FBS have no effect on survival and 10 nM PMA only causes a minor
reduction in survival.
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Figure 31. Morphological and proliferative effects of quercetagetin on tumorigenic
human prostate cells. RWPE-2 cells were incubated with quercetagetin (A) or DMSO
(B) overnight and the cell morphology examined. C. RWPE-2 cells were cultured in the
presence of DMSO, quercetagetin (25 pM), PMA (10 nM), or serum (10%). After 5
days the amount of live cells present was determined by crystal violet staining.
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CHAPTER 4
DISCUSSION
4.1. Development of an Efficient Kinase Assay for the Evaluation of Potential PIM1 Kinase Inhibitors (Specific Aim 1)
Our ELISA-based kinase assay proved to be an efficient method for determining
the potency of potential PIM-1 kinase inhibitors. It allows for the simultaneous
evaluation of numerous samples and produces accurate, reproducible results. An added
advantage is that, in contrast to many other kinase assay protocols, our assay does not
require the use of radioactive ATP.
Companies such as Calbiochem (cat # 539484), Chemicon International (cat #
GST415), and USBiological (cat # T9247-25) offer non-radioactive protein kinase assay
kits that employ protocols similar to the ELISA-based kinase assay that we have
developed. Hence, we are confident that our ELISA-based kinase assay is an effective
and robust protocol for determining the potency of PIM-1 kinase inhibitors.

4.2. Identification of a Lead Compound for a PIM-1 Kinase Inhibitor (Specific Aim
2)
4.2.1. Phage Display
Phage display is a powerful selection technique for isolating binding partners.
Using phage display we selected for PIM-1 kinase binding phage from the original Ph.D
12 phage display library (New England Biolabs). The phage particles recovered after the
3rd round of panning contained almost 100 times more PIM-1 kinase binding phage than
the original library. Hence, we are confident that our selection process was quite
successful and that the BP4 population of phage are indeed enriched for phage particles
displaying peptides that bind to the PIM-1 kinase.
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We determined the displayed peptide of 10 isolated BP4 phage by DNA
sequencing. Of particular note is the fact that 5 out of the 10 randomly chosen phage
displayed the same peptide - HGVKKRPHNPYG, which suggests that phage displaying
this peptide represented a noteworthy majority in the BP4 population of phage. As
demonstrated in Table 3, HGV was the only duplicated peptide identified; each of the
remaining 5 PIM-1 kinase binding peptides identified were unique. These data establish
that the HGV peptide effectively binds to the PIM-1 kinase.
The sequence of HGV resembles the phosphorylation sites of known PIM-1
kinase substrates. Similar to the PIM-1 kinase substrates PTPU2S, BAD, and Pimtide,
HGV contains a string of positively charged amino acids upstream of the target
phosphorylation position with a downstream proline in the +2 position (Figure 15). This
sequence similarity suggests that HGV binds to the substrate-binding site of the PIM-1
kinase, as opposed to another region of the kinase. Additionally, the pseudo-substrate
nature of HGV suggests that its interaction with the PIM-1 kinase is specific and that the
observed interaction is not due to non-specific binding mechanisms, i.e. that HGV is a
“sticky” peptide.
We anticipated that the PIM-1 kinase binding peptides would reveal a consensus
sequence for preferential binding to the PIM-1 kinase. Surprisingly, there appeared to be
no consensus sequence among the PIM-1 kinase binding peptides. This result is in
contrast to reports of similar experiments performed to identify substrate sequences of
other kinases, where a consensus sequence was identified(l 10). However, our result is
not wholly unique. In their phage display experiments Su-Jun et al identified several
substrate peptides of the Tie-2 kinase, but were not able to deduce a consensus substrate
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sequence( 109). Su-Jun et al attributed their result to the wide range of Tie-2 kinase
substrates, suggesting a broad specificity for the enzyme. It is unlikely that this
explanation is appropriate in our case. Though many PIM-1 kinase substrates have been
identified, there does appear to be a general consensus sequence for PIM-1 kinase
substrates(161).
It is possible that the lack of a consensus sequence in our results is due to our
selection methodology. In our experiments we selected for phage that bind to the PIM-1
kinase. Similar experiments performed to identify substrates of other kinases selected for
phosphorylated peptides, rather than binding partners. Consequently, it is possible that
the PIM-1 kinase binding peptides that we have identified do not contain a consensus
sequence because they do not all bind to the same region of the PIM-1 kinase. The HGV
peptide, as discussed above, is likely a pseudo-substrate of the PIM-1 kinase and thus in
all probability binds to the substrate-binding site of the PIM-1 kinase. However, the
remaining peptides identified, having no similarity to PIM-1 kinase substrate sequences,
may bind to other regions of the kinase. This would explain the lack of a consensus
sequence among our results and provide an explanation for the superior PIM-1 kinase
binding ability of HGV over the other peptides identified.
Initial in vitro kinase experiments suggested that HGV inhibits PIM-1 kinase
activity, as shown in Figure 16. However, additional experiments did not always
demonstrate that HGV is an antagonist of PIM-1 kinase activity. We considered the
possibilities that the peptide stock had either formed aggregates in solution or degraded.
Consequently, a fresh stock of HGV was synthesized (Peptron, Inc.). Unfortunately, we
were also unable to obtain consistent results from the newly synthesized stock of HGV.
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As with the original stock of HGV, similar assays performed on different days yielded
different results. In one experiment HGV would appear to have no effect on PIM-1
activity, while in a similar experiment performed on a different day HGV would
demonstrate micromolar potency against the PIM-1 kinase. We obtained similar
inconsistent results using the ELISA-based kinase assay.
The inconsistency of our results led us to consider focusing on the two other
approaches in which we were actively engaged to identify a selective inhibitor of the
PIM-1 kinase, i.e. computational drug design and identification by functional assay
screening. However, the inconsistency of the results was only one of the problems we
encountered with HGV. A second problem was the potency. In the assays where HGV
demonstrated efficacy as a PIM-1 kinase inhibitor, its IC50 was in the low micromolar
range. Our goal was to identify an inhibitor with an IC50 in the mid to low nanomolar
range, at the most.
There was also a third potential problem with HGV - it is a peptide. While
pseudo-substrate peptides have been shown to be effective inhibitors of kinases for
laboratory studies, there is some difficulty in translating their efficacy to clinical use.
Peptides tend to traverse cellular membranes poorly, making it difficult for therapeutic
peptides to reach their intracellular targets. Additionally, peptides are susceptible to the
numerous proteases found in human serum. These proteases may inactivate the peptides
before they have any effect on their targets. Thus peptides tend to perform poorly as
therapeutic drugs when administered to human subjects.
Recently a crystal structure has become available of the PIM-1 kinase in complex
with the substrate Pimtide (PDB id 2BIL). The crystal structure elucidates the
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intermolecular interactions between the kinase and its peptide substrate. With this
information it is possible to design a peptidomimetic antagonist of the PIM-1 kinase.
HGV can be modeled into the PIM-1 kinase substrate-binding site to examine its
intermolecular interactions with the kinase. Then, using HVG as a template, a small
molecule can be designed that mimics the interactions of HGV with the PIM-1 kinase.
The small molecule may have improved potency over HGV due to its specific design for
the PIM-1 kinase substrate-binding site. Additionally, because it would not be a peptide.
we do not anticipate that the small molecule would be susceptible to serum proteases, as
would HGV. Furthermore, the small molecule would be designed with molecular
properties that allow it to traverse cellular membranes.

4,2.2. Computational Design of a Novel PIM-1 Kinase Inhibitor
A. Homology Modeling
To pursue the computational design of a novel inhibitor of the PIM-1 kinase we
recognized that it would be beneficial to have a structure of the kinase. Unfortunately, at
the beginning of this project, there were no published crystal structures of the PIM-1
kinase available. With no available crystal structures, we constructed a homology model
of the PIM-1 kinase using comparative modeling techniques. Death-associated protein
kinase (DAPK) was chosen as the major template for modeling the structure of the PIM-1
kinase due to its sequence similarity to the PIM-1 kinase. There were three regions for
which the sequence similarity of DAPK was not a suitable template for modeling the
structure of the PIM-1 kinase, the loop region preceding a-helix C (the DAPK basic loop;
PIM-1 residues 72 - 88), the hinge region (PIM-1 residues 122 - 127) and alpha helix G
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(PIM-1 residues 243 - 270). For the loop region preceding a-helix C and the hinge
region, an extensive sequence search did not reveal any known kinases with similar
sequences to the PIM-1 kinase in those regions. Consequently we employed the loop
generation function within the HOMOLOGY module of Insightll (Accelrys), as
described in the methods section, to model these regions. Recently resolved crystal
structures of the PIM-1 kinase identify both of these regions as structurally
unique(157; 158), confirming that no known suitable templates for these regions exist. In
contrast, an extensive sequence search identified cAMP-dependent kinase as an
appropriate template for modeling the G-helix region of the PIM-1 kinase; hence the
coordinates of cAMP-dependent kinase, rather than DAPK, were used to model the
structure of the PIM-1 kinase in that region.
The recent publication of a PIM-1 kinase a crystal structure afforded us the
opportunity to examine the accuracy of our model. As shown in Figure 21, our model is
structurally similar to the crystal structure throughout the vast majority of the molecule.
having an RMSD of 3.14 A to the backbone atoms of the crystal structure. It has been a
long-standing observation that homology models are most reliable in the regions in which
the model shares high sequence similarity to the template(162;163), with non-conserved
loops representing the major contributions to model inaccuracy(162-164).

As shown in

Table 4, our results typify these observations. The RMS deviation in the structurally
conserved regions (SCRs) (1.33 A) is considerably smaller than that of the non-conserved
loop regions (2.15 A - 4.65 A). Specifically, much of the RMS deviation in the model is
due to the loop region preceding a-helix C, one of the regions for which we could find no
suitable template. The loop region preceding a-helix C is 16 amino acids long, which
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made randomly generating an accurate conformation extremely difficult. (By
comparison, the 2nd longest randomly generated non-conserved loop, the activation loop,
is 8 amino acids long.)
Chothia and Lesk have shown that the RMS deviation between separate crystal
structures of the same protein can be as much as 0.4 A, and that proteins sharing 50%
sequence identity can be expected to have RMS deviations close to 1.0 A(165). The
degree of RMS deviation that can be expected for homology models has also been
assessed. Guex et al performed an evaluation of 1,201 protein homology models created
by the SWISS-MODEL automated comparative modeling program(166).
Experimentally determined protein structures corresponding to each of the homology
models were also available. Guex et al compared the RMS deviations of homology
models built using template structures with 25% - 95% sequence identity to the target
protein. The actual protein being modeled was not used as a template structure to build
the homology models. Their results confirmed an inverse relationship between sequence
identity and RMS deviation, i.e. as sequence identity increased, the degree of RMS
deviation between homology models and experimentally determined structures of the
same protein decreased. For the 125 homology models built using template structures
with 25% - 29% sequence identity to the target protein (our PIM-1 kinase homology
model falls into this category), 30% had an RMSD < 3 A and 46% had an RMSD < 4 A.
Hence, an RMSD of 3.14 A for the PIM-1 kinase homology model is well within the top
half and more likely within the top third of the range of expected RMS deviations.
Figure 21 demonstrates that we accurately modeled the secondary structures of
the PIM-1 kinase (p-sheets and a-helices) and that areas of dissimilarity are found in
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loop structures. Most importantly, we accurately modeled the ATP binding pocket,
where the RMSD between the backbone atoms of the model and the crystal structure was
only 1.46 A. It is most important that this region is accurate because our docking studies
were conducted in the ATP binding pocket of the model

B. Docking
We used the AFFINITY module of Insightll (Accelrys) to dock a test set of
flavonoids to the PIM-1 kinase model. Each flavonoid was docked in the ATP binding
site of the model in 10 different orientations to comprehensively sample the
conformational space within the pocket. The interaction energy (IE) was determined
computationally between the flavonoid and the PIM-1 kinase model for each docked
orientation. The orientation with the lowest (smallest) IE was considered to be the best
representation of the true docked orientation of the flavonoid. We performed a
correlation analysis to determine if the computational measure of binding (IE) correlated
with potency (log IC50) for the set of flavonoids. As shown in Table 5, there was a poor
correlation between IE and log IC50 (R2 = 0.44).
These data suggest an inadequacy in the PIM-1 kinase model, the docking
algorithm, and/or the scoring algorithm employed. Homology models have been shown
to be useful tools in the rational design of site-directed mutagenesis experiments and in
molecular replacement in crystallography (for review see (167)). However, it has been
suggested that homology models built using templates lacking a high degree of sequence
identity to the target sequence (<70%) are not useful for ligand binding studies(168). In
our case, however, it is clear that the PIM-1 kinase model was not the source of the poor
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correlation between IE and potency, as docking of the test set of flavonoids to the PIM-1
kinase crystal structure did not improve the correlation between IE and log IC50. It is
more likely that an inadequacy exists in the docking and/or scoring algorithms employed.
Hence, we performed additional docking experiments in an effort to identify parameters
that would obtain more accurate results.
Including explicit water molecules in the ATP pocket did not improve the
correlation between IE and log IC50. Using a distance dependent dielectric constant of 4,
and using no distance dependent dielectric constant were both unsuccessful at improving
the accuracy of the docking and/or scoring method; neither were our results improved by
using the CVFF force field instead of the CFF force field.
We were able to determine the inadequacy of the docking/scoring method when
crystal structures of the PIM-1 kinase in complex with 4 flavonoids (quercetin,
quercetagetin, myricetin, and S^S’^’^’-pentahydroxyflavone) were made available to
us (a generous gift from Plexxikon, Inc.). Examining the crystal orientations of the
flavonoids revealed that the docked poses with the lowest IE represented the crystal pose
of only one of the flavonoids - quercetin. The docked pose with the lowest IE for the
remaining 3 flavonoids (quercetagetin, myricetin, and S^S’^S’-pentahydroxyflavone)
was not the same orientation as the crystal pose. Therefore, the docking/scoring method
employed was unable to accurately identify the correctly docked orientation of flavonoids
within the ATP pocket of the PIM-1 kinase resulting in poor correlations between the
computational measure of binding and potency.
Obtaining poor correlations between computational measures of docking and
empiric measures of biological activity is not unique to our experience. Ferrara et al have
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performed similar experiments using nine different scoring functions (CHARMm,
DrugScore, Autodock, DOCK-energy, DOCK-contact, DOCK-chemical, PMF, GOLD,
and Chemscore) to predict the binding affinities of ligands in 189 and 116 complexes,
with the highest correlation achieved being R2 = 0.51 and R2 = 0.43, respectively(169).
These results are similar to the correlation of R2 = 0.44 achieved in our experiments.
However, Ferrara et al were able to successfully discriminate near-native from misdocked
ligand conformations approximately 80% of the time when using 5 of the 9 scoring
functions (CHARMm, DOCK-energy, DrugScore, ChemScore, and AutoDock). These
data lend further support to the conclusion that it was necessary to improve our
docking/scoring process. Consequently, we employed a different computational method
to identify quantitative structure activity relationships for the set of flavonoid compounds
- comparative molecular field analysis.

C. Comparative Molecular Field Analysis (CoMFA)
Using CoMFA we were able to develop a quantitative structure activity
relationship for flavonoid binding to the PIM-1 kinase. The model accurately predicts the
potency of both the training and test sets of flavonoids. The correlation between
predicted -log IC50 and experimental -log IC50 for the training and test sets were R =
0.805 and R2 = 0.826, respectively. These data demonstrate that when using the
parameters we employed, CoMFA provides a superior predictive model of flavonoid
inhibitor potency than affinity docking.
We used the CoMFA model to elucidate the important 3-dimensional properties
associated with flavonoid binding to the PIM-1 ATP binding site. Sixty-three percent of
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the contributions to the model were steric, while 37% were electrostatic. These findings
suggest that flavonoid binding to the PIM-1 kinase is affected more by steric factors than
by electrostatic factors.
The steric contours reveal that the PIM-1 kinase ATP binding site is sterically
hindered above and below the plane of the bound flavonoid.

This is consistent with the

findings of Kumar et al, who reported that an inhibitor scaffold ligand of the PIM-1
kinase made use of hydrophobic interactions to bind to the PIM-1 kinase ATP binding
pocket(158). Specifically, the resolved co-crystal structure elucidated that the inhibitor
scaffold was sandwiched from above by the hydrophobic residues Lys44, Val52 and Ala65
and from below by Leu174 and He185. With this steric, hydrophobic hindrance above and
below the plane of the bound inhibitor, the planar conformation of the flavone class of
compounds allows them to fit well into the sterically restricted space of the PIM-1 kinase
ATP binding site. It is likely that this planar conformation is one of the major reasons
that flavonoids as a class of compounds appear to inhibit the PIM-1 kinase more
effectively than other classes of compounds that are known kinase inhibitors. As
reported in the results section, our screen of 1,200 small molecules with structures similar
to known kinase inhibitors revealed that 6 out of the 7 most potent PIM-1 kinase
antagonists in the library were flavonoids. The seventh compound, and only nonflavonoid, was an anthraquinone, which is also a planar molecule. The steric hindrance
also explains why the (R)- and (S)- flavanones, which have a chiral carbon at the C2
position and therefore are not flat, are inferior PIM-1 kinase antagonists to the flavones,
which are flat (see Figure 23). Thus, we have identified that due to the sterically
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restricted nature of the PIM-1 kinase ATP binding site, a planar conformation is a
favorable property for a selective PIM-1 kinase ATP competitive inhibitor.
As demonstrated by Figure 25, volume of the ligand also appears to play a role in
the potency of flavonoid compounds as PIM-1 kinase antagonists. This feature is
probably also related to the sterically restricted nature of the binding site. It seems that
potency of a flavonoid is reduced when the volume of the flavonoid is too small to
adequately fill the ATP binding pocket and exploit potential interactions to the kinase.
Similarly, if the volume of the flavonoid is too large the restrictive nature of the binding
pocket results in reduced efficiency of binding and inferior potency. A volume of about
218 A3, the volume of quercetagetin, appears to be near optimal for flavonoid inhibitors
of the PIM-1 kinase.
In addition to the strong correlation between predicted -log IC50 and experimental
-log IC50 for the training and test sets of flavonoids, we validated the CoMFA model by
superimposing the crystal structure of the PIM-1 kinase in complex with quercetagetin
onto the CoMFA model. As illustrated in Figure 24, the crystal structure validates the
CoMFA model by elucidating the amino acid residues that contribute to the steric and
electrostatic contours of the model. This type of analysis is fairly unique, as CoMFA
models are usually employed when the structure of the enzyme or protein is unknown.
We were able to find some examples of similar types of analyses in the literature where
the contours for a CoMFA model of a protein were combined with the structure of the
enzyme(120;170-172). In each case, as in our case, the combination of the CoMFA
contours with the enzyme structure improved the pharmacophore model, allowing for a
more informed and specific structure-based design effort.
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Using our combined pharmacophore model we designed SH25, a quinazolinol, to
be a potent, selective PIM-1 kinase antagonist. SH25, with the addition of a positively
charged amine group at the C8 position, should have improved interactions with the
171

negatively charged acidic side chains of Glu " , Asp

17/c

, Asp

171

, and Glu

171

; and the

addition of a Cf atom at the 6’ position should improve the steric interactions of the
molecule with the PIM-1 kinase ATP binding site.
We designed SH25 as a quinazolinol, rather than a flavonoid, because historically
flavonoids have met with complications related to inadequate selectivity and potency
when developed for clinical use as molecular therapeutics. For example, phase II clinical
trials have demonstrated that flavopiridol, a flavonoid inhibitor of cyclin-dependent
kinases, is ineffective in the treatment of non-small lung cell cancer(173), metastatic
renal cancer(174), gastric cancer(175), metastatic malignant melanoma(176), metastatic
androgen-independent prostate cancer(177), and advanced colorectal cancer(178).
Additionally, in many of the clinical trials flavopiridol induced an increased incidence of
vascular thrombotic events(173-175).
In contrast, SH25, a quinazolinol, retains much of the conformational properties
of a flavone, including the important quality of being planar, but is a member of a class of
compounds that have shown clinical efficacy for the treatment of human diseases. For
example, the quinazoline derivative Tarceva (erlotinib) is an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. In clinical trials, where patients with non
small cell lung cancer were treated with Tarceva or placebo, treatment with Tarceva
improved the 1-year survival rate by 45% and the median survival rate by 42.5% . As a
result, Tarceva is currently FDA approved and indicated for the treatment of non-small
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cell lung cancer. Additional quinazoline kinase inhibitors are also currently under
investigation. Cl-1033, an irreversible quinazoline inhibitor of the ErbB family of
kinases, has shown promising efficacy against human tumors in mouse xenograft models
(for review see (179)). GW-2016, a quinazoline inhibitor of the ErbB-2 and EGER
tyrosine kinases, has been shown to induce growth arrest and cell death in human cancer
cell lines(180). Lastly, MLN-518, a quinazoline inhibitor of the FLT, KIT, and PDGFR
tyrosine kinases, has been shown to preferentially inhibit the growth of human AML
FLT3-ITD+ over ITD- blast colonies(181). Internal tandem duplications (ITD) of the
FLT-3 receptor tyrosine kinase are found in about 30% of human cases of acute
myelogenous leukemia (AML) and is associated with poor prognosis(182-186). Hence,
we anticipate that the quinazolinol SH25 will demonstrate improved efficacy over its
counterpart flavonoid inhibitors.
Lipinski et al have described a set of four characteristics to predict poor
absorption or permeation for potential drugs(187). These set of characteristics are
commonly known as the rule of five because all of the cutoff values are 5 or a multiple of
5. The criteria that predict poor absorption or permeation are: (1) the compound contains
more that 5 hydrogen bond donors, (2) the molecular weight of the compound is >500,
(3) the octanol-water partition coefficient (Log P) is >5, or (4) the sum of nitrogen and
oxygen atoms (hydrogen bond acceptors) is greater than 10. If a compound fails any two
of the criteria it is likely that the compound will have poor absorption or permeation.
Considering the rule of 5 as it applies to SH25, the compound fails only one of the
criteria - it contains more than 5 hydrogen bond donors (SH25 contains 9 hydrogen bond
donors). Thus, SH25 can be expected to have adequate absorption as a therapeutic drug.
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The CoMFA model predicts SH25 to be as potent a PIM-1 kinase antagonist as
quercetagetin, the most potent flavonoid PIM-1 kinase inhibitor identified. Additionally,
we anticipate that by maximizing the intermolecular interactions between SH25 and the
PIM-1 kinase ATP binding pocket, the selectivity of SH25 for the PIM-1 kinase will be
an improvement over that of quercetagetin. Moreover, SH25 may be a superior
molecular therapeutic than quercetagetin due to its quinazolone-derived backbone
structure. We are currently having SH25 synthesized, after which its potency and
selectivity for the PIM-1 kinase will be determined.

4.2.3. Screening for a Small Molecule Inhibitor of the PIM-1 Kinase
A. Screening
Using our ELISA-based kinase assay we screened a 1,200 compound library of
small molecules having structural similarity to known kinase inhibitors. The library
contained many different classes of compounds, yet 6 of the 7 most potent inhibitors of
the PIM-1 kinase were flavonoids. These results suggested that the flavonoid class of
compounds is particularly well suited to serve as PIM-1 kinase antagonists.
The most potent PIM-1 kinase inhibitor identified in the library was quercetin.
With an IC50 of 1.1 pM the potency of quercetin was promising, however, quercetin had
been shown not only to inhibit other kinases, but also many other classes of enzymes (for
review see (188)). As a result we screened additional flavonoids to identify more potent
and selective flavonoid inhibitors of the PIM-1 kinase. After screening 21 flavonoids for
inhibitory activity against the PIM-1 kinase, we identified quercetagetin as the most
potent (IC50 = 0.34 pM).
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B. Characterization of quercetagetin as a selective inhibitor of the PIM-l kinase
Quercetagetin inhibits PIM-l kinase by competitively binding to the ATP-binding
site of the kinase, as demonstrated by Lineweaver-Burk analysis. X-ray crystallography
of the PIM-l kinase in complex with quercetagetin confirms that quercetagetin binds in
the ATP binding pocket.
We have also shown that quercetagetin is selective for the PIM-l kinase over
RSK2, PKA, JNKlal, Aurora-A, c-RAF, PKC0, and even the PIM-2 kinase. These data
suggest that quercetagetin is not only a potent inhibitor of the PIM-l kinase, but also a
selective inhibitor of the PIM-l kinase. To the best of our knowledge this is the first
report of a selective inhibitor of the PIM-l kinase and consequently represents a
significant advancement for the study of PIM-1 kinase activity.
The finding that quercetagetin is approximately 10 times more potent against the
PIM-l kinase than the PIM-2 kinase was an unexpected discovery. Due to the high
sequence similarity between the PIM-l and PIM-2 kinases, especially within the ATPbinding pocket, we did not anticipate that the potency of quercetagetin for the PIM-l
kinase over the PIM-2 kinase would be so great. This result prompted us to examine the
ATP-binding pockets of the two kinases.
Using the PIM-l kinase-quercetagetin co-complex crystal structure as a reference,
we determined that there is only 1 non-identical residue between the PIM-l and PIM-2
kinases within 4 A of the bound quercetagetin. Val126 in the PIM-l kinase is substituted
with an alanine residue in the same position in the PIM-2 kinase. Although valine and
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alanine are similar hydrophobic residues, the significance of the substitution is elucidated
more clearly when considering the hinge region in its entirety.
In the hinge region the two kinases contain only one additional non-identical
residue; Glu124 in the PIM-1 kinase is substituted with a leucine residue in the same
position in the PIM-2 kinase (see Figure 20). The crystal structure of the PIM-1 kinase in
complex with quercetagetin reveals that the side chain of Glu124 in the PIM-1 kinase
extends into the aqueous solvent. While this position is well suited for the charged side
chain of the Glu124 residue found in the PIM-1 kinase, it is not a favorable position for the
hydrophobic side chain of the leucine residue found in the same position in the PIM-2
kinase. To better accommodate the hydrophobic leucine residue, it is likely that the hinge
region of the PIM-2 kinase adopts a different structural conformation than that of the
PIM-1 kinase. This conformational change is supported by the substitution of Val 126 in
the PIM-1 kinase with the alanine residue found in the same position in the PIM-2 kinase.
Substitution of a valine residue for a smaller alanine residue would allow for increased
flexibility while retaining the hydrophobic nature of that region of the hinge. The
increased flexibility may be necessary for the hinge of the PIM-2 kinase to adopt a
conformation that does not require the hydrophobic side-chain of leucine to extend into
the aqueous solvent. Because the hinge region forms one border of the ATP-binding
pocket and interacts with the bound quercetagetin it is possible that the structure of the
PIM-2 kinase hinge region reduces the affinity of quercetagetin for the PIM-2 kinase.
Such a structural difference between the PIM-1 and PIM-2 kinases could explain the
observed difference in the potency of quercetagetin for the two kinases.
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Fabian et al further elucidate the uniqueness of a potent, selective inhibitor of the
PIM-1 kinase. In their recently published article, they identified only 3 out of 20 kinase
inhibitors as having binding interactions with the PIM-1 kinase - staurosporine.
LY333531, and flavopiridol(189). Staurosporine is a pan kinase inhibitor and was shown
to bind to most of the 119 kinases assayed. Similarly, LY333531, a staurosporine
derivative, also lacked selectivity for the PIM-1 kinase. Interestingly, a brief analysis of
the structure of flavopiridol reveals that it is a flavonoid. Given the data we have shown
demonstrating the proclivity of flavonoid compounds to inhibit the PIM-1 kinase, it is not
an unexpected finding that flavopiridol also binds to the PIM-1 kinase. Flavopiridol,
which is a known cyclin-dependent kinase inhibitor, was shown to bind to several other
kinases, revealing that it also lacks selectivity for the PIM-1 kinase. These data further
demonstrate the lack of a selective inhibitor of the PIM-1 kinase until our current
identification of quercetagetin as a selective PIM-1 kinase antagonist.
In their examination of 70 co-crystal structures of the PIM-1 kinase in complex
with various inhibitor scaffolds, Kumar et al identified a hydrogen bond network that was
common in almost all of the complexes(l 58). The network involves a series of hydrogen
bonds in the ATP binding pocket between Lys67, Glu89, the backbone amide of Phe187,
and a conserved bound water molecule. Kumar et al observed that many of the ligands
interacted with this key hydrogen bond network and identified it as a “key structural
signature in PIM-1.” In many of the complexes the ligand accessed this hydrogen bond
network by interacting with the conserved bound water molecule. Kumar et al
hypothesized that ligand binding to the PIM-1 kinase could possibly be improved by
substituting groups onto the inhibitor scaffold that would release the bound water and

111

interact directly with Lys67 or Glu89. Examination of the PIM-1 kinase-quercetagetin co
crystal complex reveals that quercetagetin binds to the PIM-1 kinase in this precise
manner. The 4’ hydroxyl group of quercetagetin displaces the conserved bound water
molecule (found in > 90% of the 70 co-crystal structures examined by Kumar et al), and
forms a hydrogen bond directly to Glu89. It is likely that this interaction is a major factor
in the selectivity and potency of quercetagetin against the PIM-1 kinase. Furthermore,
the hydroxyl group in position C3 of quercetagetin forms a direct hydrogen bond to the
backbone carbonyl of Glu121, mimicking a canonical hinge-ATP interaction. Hence, the
co-crystal structure demonstrates that quercetagetin is well-suited to bind to the ATPbinding pocket of the PIM-1 kinase.

4.3. Determine the Effect of the Lead PIM-1 Kinase Inhibitor Compound on
Mammalian Cells (Specific Aim 3)
We have demonstrated that quercetagetin effectively inhibits PIM-1 kinase
activity in mammalian cells. Quercetagetin does not require any structural modifications
to traverse the cellular membrane, neither are any special protocols necessary to
permeabilize the cells and allow quercetagetin to enter. Applying Lipinski’s rule of five
to quercetagetin, the flavonoid fails only one of the criteria - it has more than 5 hydrogen
bond donors. Thus quercetagetin can be expected to have adequate absorption and
permeation as a therapeutic drug. These characteristics, in addition to the selectivity and
potency of quercetagetin for PIM-1 kinase, make it a useful tool for the inhibition of
PIM-1 kinase for laboratory studies. Additionally, quercetagetin may serve as a useful
template for the design of more potent inhibitors of the PIM-1 kinase outside of the
flavonoid class of compounds for use as molecular therapeutics.
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In summary, we have described three approaches to the identification of a
selective inhibitor of the PIM-I kinase. Through phage display we have identified a
pseudo-substrate peptide that may serve as an effective template for the design of a
peptidomimetic inhibitor of the PIM-1 kinase. We have also created a CoMFA model of
the PIM-1 ATP binding pocket using a set of flavonoid probes. This CoMFA model
accurately predicts the potency of flavonoid antagonists of PIM-1 kinase activity.
Furthermore, the model allowed us to identify important steric and electrostatic features
of the PIM-1 ATP binding pocket. Based on the model, we have designed a quinazolinol
compound (SFI25) that maximizes the potential intermolecular interactions within the
ATP biding pocket of the PIM-1 kinase. We anticipate that SH25 will be as potent an
inhibitor as quercetagetin with an improved selectivity profile. Lastly, we have identified
quercetagetin as a potent, selective inhibitor of the PIM-1 kinase. Quercetagetin inhibits
PIM-1 kinase activity in vitro and in mammalian cells, and thus may serve as an effective
tool for the selective inhibition of the PIM-1 kinase in laboratory studies.
The overexpression ofpim-1 has been shown to predispose to the development of
murine and human cancers, while pim-l knockout mice show no major abnormalities
(due to functional compensation by PIM-2 and PIM-3). These findings are pertinent
because they demonstrate that while the PIM-1 kinase is involved in tumorigenesis in
cancer cells, the abolition of PIM-1 kinase activity has little adverse effects in normal
cells. Hence, selective inhibition of the PIM-1 kinase may be an effective approach for
the therapeutic treatment of pim-1 expressing cancers resulting in little adverse effects to
normal cells. The identification of a potent, selective inhibitor of the PIM-1 kinase, such
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as quercetagetin, provides a simple tool for evaluating the effects of abolishing PIM-1
kinase activity in transformed cells.
An intriguing possibility for designing additional potent inhibitors of the PIM-1
kinase is to conjugate a PIM-1 kinase pseudo-substrate to an ATP competitive inhibitor
of the PIM-1 kinase. The underlying concept is that the PIM-1 pseudo-substrate region
will direct the inhibitor to the PIM-1 kinase, resulting in improved potency and selectivity
over the ATP competitive inhibitor alone. Similar approaches have been successfully
employed for the design of kinase specific inhibitors. For example, the tyrosine kinase
inhibitor, genistein, was shown by Uckun et al to inhibit the epidermal growth factor
receptor (EGF-R) tyrosine kinase in breast cancer cells with an IC50 greater than 10 pM.
However, genistein conjugated to EGF (EGF-Gen) inhibited the EGF-R tyrosine kinase
at nanomolar concentrations(190). In addition, selective inhibitors of cyclin-dependent
kinase 1(191), protein kinase C(192), and cAMP-dependent protein kinase(192) have
been successfully developed by conjugating a pseudosubstrate to an ATP-competitive
inhibitor.
A similar approach can be applied to the design of a potent, selective inhibitor of
the PIM-1 kinase. Quercetagetin can be conjugated to the HGV peptide to create a PIM1-directed small molecule inhibitor. Additionally, an HGV peptidomimetic can be
conjugated to quercetagetin or even to SH25 to create new PIM-1 kinase directed small
molecule inhibitors. The totality of the work we have conducted in this project has laid a
foundation for the design of molecular therapeutics targeting the PIM-1 kinase that can
potentially be more potent and selective than quercetagetin, (the inhibitor characterized
here) and may serve as effective agents for the treatment of pim-1 expressing cancers.
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The significance of the work we have performed in this project is highlighted in a
recently published editorial by Francis Giles entitled “A Pim Kinase Inhibitor,
Please(193).” The editorial was prompted by an article in which Hammerman et al
demonstrated that the PIM-2 kinase confers rapamycin resistance on non-transformed
hematopoietic cells(194). Rapamycin inhibits mTOR kinase driven cell proliferation by
preventing mTOR kinase phosphorylation of 4EBP-1. However, the PIM-2 kinase,
which is not inhibited by rapamycin, also phosphorylates 4EBP-1, thereby conferring
rapamycin resistance on pim-2 expressing cells. Hammerman et al have also shown that
the PIM-1 kinase partially protects cells from rapamycin-induced inhibition of cell
growth(194). Additionally, our own laboratory experiments have shown that the PIM-1
kinase also phosphorylates 4EBP-1, hence it is not surprising that the PIM-1 kinase
provides partial resistance to the effects of rapamycin. In his editorial, Giles comments
that up-regulation of PIM kinases may be a mechanism of tumor resistance to rapamycin.
He calls for the development of PIM kinase inhibitors, which alone or in combination
with mTOR kinase inhibitors, may be effective anti-cancer agents. The work we have
presented in this project answers that call and lays a strong foundation for the further
development of PIM kinase inhibitors.
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